SECURITIES PURCHASE
AGREEMENT
Dated as of May 24, 2010
by and among
LA JOLLA PHARMACEUTICAL COMPANY
and
THE PURCHASERS LISTED ON EXHIBIT A

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT dated as of May 24, 2010 (this “ Agreement ”) by and among La Jolla Pharmaceutical Company, a Delaware corporation (the “ Company ”), and each of the purchasers of (i) shares of common stock of the Company, (ii) shares of preferred stock of the Company, (iii) warrants to purchase shares of preferred stock of the Company and (iv) warrants to purchase units consisting of shares of preferred stock of the Company and warrants to purchase additional shares of preferred stock of the Company, whose names are set forth on Exhibit A attached hereto (each a “ Purchaser ” and collectively, the “ Purchasers ”).

The parties hereto agree as follows:

ARTICLE 1

PURCHASE AND SALE OF COMMON STOCK, PREFERRED STOCK AND WARRANTS

1.1 Purchase and Sale of Common Stock, Preferred Stock and Warrants . Upon the following terms and conditions, the Company shall issue and sell to the Purchasers, and the Purchasers shall purchase from the Company, securities for an aggregate purchase price of $ $6,003,113.04 at the Closing (as defined in Section 1.2(b)), consisting of: (i) 28,970,435 shares of the Company’s common stock, par value $0.01 per share (the “ Common Stock ”), for an aggregate purchase price of $869,113.05, at a price per share equal to $0.03; (ii) 5,134 shares of the Company’s Series C-1 Preferred Stock, par value $0.01 per share (the “ Series C-1 Preferred ”), for an aggregate purchase price of $5,134,000, at a price per share equal to $1,000; (iii) warrants, in substantially the form attached hereto as Exhibit B (the “ Cashless Warrants ”), to purchase an aggregate amount of up to 5,134 shares of the Company’s Series D-1 Preferred Stock, par value $0.01 per share (the “ Series D-1 Preferred ”), at an exercise price per share equal to $1,000; and (iv) warrants, in substantially the form attached hereto as Exhibit C (the “ Cash Warrants ”), to purchase an aggregate of 10,268 units, at an exercise price of $1,000 per unit, where each unit consists of (A) one share of the Company’s Series C-2 Preferred Stock, par value $0.01 per share (the “ Series C-2 Preferred ”); and (B) a warrant, in substantially the form attached as Exhibit A to the Cash Warrants (the “ Subsequent Cashless Warrants ”), to purchase one share of the Company’s Series D-2 Preferred Stock, par value $0.01 per share (the “ Series D-2 Preferred ” and, together with the Series C-1 Preferred, Series C-2 Preferred and Series D-1 Preferred, the “ Preferred Stock ”). The Cashless Warrants, Cash Warrants and Subsequent Cashless Warrants shall be collectively referred to herein as the “ Warrants .” At the Closing, the Company shall deliver to each Purchaser: (i) a stock certificate registered in the name of such Purchaser, or in the name(s) of such nominee(s) as designated by such Purchaser, representing in the aggregate the number of shares of Common Stock set forth opposite such Purchaser’s name on Exhibit A attached hereto; (ii) a stock certificate registered in the name of such Purchaser, or in the name(s) of such nominee(s) as designated by such Purchaser, representing in the aggregate the number of shares of Series C-1 Preferred set forth opposite such Purchaser’s name on Exhibit A attached hereto; (iii) a Cashless Warrant to purchase the number of shares of Series D-1 Preferred set forth opposite such Purchaser’s name on Exhibit A attached hereto and (iv) a Cash Warrant to purchase the number of shares of Series C-2 Preferred set forth opposite such Purchaser’s name on Exhibit A attached hereto. The Company and the Purchasers are executing and delivering this Agreement in accordance with and in reliance upon the exemption from securities registration afforded by Section 4(2) of the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “ Securities Act ”), including Regulation D (“ Regulation D ”), and/or upon such other exemption from the registration requirements of the Securities Act as may be available with respect to any or all of the investments to be made hereunder.

1.2 Purchase Price and Closing .

(a)  Subject to the terms and conditions hereof, the Company agrees to issue and sell to the Purchasers and, in consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the Purchasers, severally and not jointly, agree to purchase the Securities (as defined in Section 1.3(b)) for an aggregate initial purchase price of $6,003,113.04, without giving effect to the potential mandatory exercise of the Cash Warrants (the “ Purchase Price ”). At the Closing, each Purchaser shall deliver the applicable portion of the Purchase Price as indicated on Exhibit A hereto by wire transfer of immediately available funds to the Company.

(b)  The closing under this Agreement (the “ Closing ”) shall take place on or before May 28, 2010 (the “ Closing Date ”), provided, that all of the conditions set forth in Article 5 hereof and applicable to the Closing have been fulfilled or waived in accordance herewith. The Closing shall take place at the offices of the Company, 4365 Executive Drive, 3 ^rd Floor, San Diego, California 92121 at 2:00 p.m. Pacific Standard Time, or at such other time and place as the parties may agree. Subject to the terms and conditions of this Agreement, at the Closing, each Purchaser shall purchase and the Company shall issue and deliver or cause to be delivered to each Purchaser Securities in the amounts set forth opposite the name of such Purchaser on  Exhibit A  hereto.

1.3 Conversion Shares; Reverse Stock Split .

(a)  The Company shall (i) on or before the date that is three Weeks (as defined in the Certificate of Designations as defined in Section 2.1(f)) following the Closing Date, file a preliminary proxy statement on Schedule 14A with the Securities Exchange Commission (“ SEC ”) relating to: (A) not less than two (2) separately proposed reverse stock splits of the Company’s outstanding shares of Common Stock (each a “ Reverse Split ” and, together, the “ Reverse Splits ”), (B) an amendment to the Company’s Certificate of Incorporation (the “ Charter Amendment ”) to (y) increase the number of shares of authorized Common Stock (the “ Authorized Share Increase ”), and (z) decrease the par value of the Common Stock, the Company’s Series A Preferred Stock and the Preferred Stock to $0.0001 per share, (C) the election of directors, and (D) the adoption of a new equity compensation plan and the amendment to the Company’s existing employee stock purchase plan to increase the number of shares available thereunder, provided that such new equity compensation plan and amended employee stock purchase plan shall each have been approved by the Purchasers holding at least 66-2/3% of the then outstanding Preferred Stock held by all holders of Preferred Stock other than any Defaulting Purchaser (as defined in Section 4.3) (the “ Requisite Holders ”) (such proxy statement being referred to herein as the “ Required Proxy Statement ” and such proposals being the “ Meeting Proposals ”), and (ii) hold the stockholder meeting relating to the Reverse Splits and the Charter Amendment (the “ Requisite Meeting ”) on or before the date that is (A) seven Weeks following the determination that the Required Proxy Statement will not be reviewed by the SEC or (B) seven Weeks following the completion of any review of the Required Proxy Statement by the SEC, as applicable. The ratio of the Reverse Splits, the date upon which any Reverse Split shall be effective and the amount of the Authorized Share Increase shall each be determined by the Company’s Board of Directors and shall each be approved by the Requisite Holders. No Reverse Split nor the Authorized Share Increase shall be effected without the approval of the Company’s Board of Directors and the Requisite Holders as set forth in the preceding sentence. Each Purchaser holding any securities of the Company as of the record date for the Requisite Meeting agrees: (a) with respect to any shares held in record name, to appoint authorized representatives of the Company as its proxies to vote all shares of Common Stock then held by such Purchaser that are eligible to vote in favor of the Meeting Proposals, and (b) with respect to any shares of Common Stock held in street name, to instruct the brokerage firm having custody of such shares of Common Stock to appoint authorized representatives of the Company as its proxies to vote all shares of Common Stock then beneficially held by such Purchaser that are eligible to vote in favor of the Meeting Proposals.

(b)  Any shares of Common Stock issuable upon conversion or otherwise in respect of the Preferred Stock are herein referred to as the “ Conversion Shares .” The Common Stock issued or issuable under this Agreement, the Preferred Stock, the Warrants and the Conversion Shares are sometimes collectively referred to herein as the “ Securities .”

(c)  Without limiting the other rights or remedies of the Purchasers under this Agreement or the Certificate of Designations (as defined in Section 2.1(f)), in the event that the Company has not for any reason held the Requisite Meeting on or prior to January 13, 2011 (the “ Meeting Deadline Date ”), then the Company shall pay to each Purchaser, on (i) the Meeting Deadline Date and (ii) the last day of each Week elapsed following the Meeting Deadline Date until the Requisite Meeting is held, in each instance set forth in clauses (i) and (ii), a cash payment in an amount equal to three percent (3%) of the purchase price paid by such Purchaser for shares of Series C-1 Preferred at the Closing.

ARTICLE 2

REPRESENTATIONS AND WARRANTIES

2.1 Representations and Warranties of the Company . The Company hereby represents and warrants to the Purchasers, as of the Closing Date, except (a) as set forth in the Public Filings (as defined in Section 2.1(g)) or (b) on the schedule of exceptions attached hereto with each numbered schedule thereof corresponding to the section number herein (the “ Schedule of Exceptions ”), as follows:

(a)  Organization, Good Standing and Power . The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. The Company does not have any direct or indirect Subsidiaries (as defined in Section 2.1(h)) or own securities of any kind in any other entity except as set forth on Schedule 2.1(h) hereto. The Company and each such Subsidiary is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary except for any jurisdiction(s) (alone or in the aggregate) in which the failure to be so qualified will not have a Material Adverse Effect. For the purposes of this Agreement, “ Material Adverse Effect ” means any material adverse effect on the business, operations, properties, prospects, or financial condition of the Company and its Subsidiaries and/or any condition, circumstance, or situation that would prohibit or otherwise materially interfere with the ability of the Company to perform any of its material obligations under this Agreement or any of the Transaction Documents (as defined in Section 2.1(b)) in any material respect.

(b)  Authorization; Enforcement . Each of the Company and its Subsidiaries (as applicable) has the requisite corporate power and authority to enter into and perform this Agreement, the Warrants and the Officer’s Certificate to be delivered by the Company, dated as of the Closing Date, substantially in the form of Exhibit D attached hereto (the “ Officer’s Certificate ” and collectively with this Agreement and the Warrants, the “ Transaction Documents ”) and to issue and sell the Securities in accordance with the terms hereof. The execution, delivery and performance of the Transaction Documents by the Company and each Subsidiary of the Company party thereto and the consummation by it of the transactions contemplated thereby have been duly and validly authorized by all necessary corporate action, and, except as set forth on Schedule 2.1(b) or as otherwise contemplated herein, no further consent or authorization of the Company, any Subsidiary or their respective Boards of Directors or stockholders is required. When executed and delivered by the Company and each Subsidiary of the Company party thereto, each of the Transaction Documents shall constitute a valid and binding obligation of the Company and each Subsidiary, as applicable, enforceable against the Company and each Subsidiary, as applicable, in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.

(c)  Capitalization . The authorized capital stock of the Company and the issued and outstanding shares of capital stock of the Company as of the Closing Date is set forth on Schedule 2.1(c) hereto. All of the outstanding shares of the Common Stock and any other outstanding security of the Company have been duly and validly authorized. Except as set forth in this Agreement, the Public Filings or as set forth on Schedule 2.1(c) hereto, no shares of Common Stock or any other security of the Company are entitled to preemptive rights or registration rights and there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company. Furthermore, except as set forth in this Agreement and as set forth on Schedule 2.1(c) hereto, there are no equity plans, contracts, commitments, understandings, or arrangements by which the Company is or may become bound to issue additional shares of the capital stock of the Company or options, securities or rights convertible into shares of capital stock of the Company. Except for customary transfer restrictions contained in agreements entered into by the Company in order to sell restricted securities or as provided on Schedule 2.1(c) hereto, the Company is not a party to or bound by any agreement or understanding granting registration or anti-dilution rights to any person with respect to any of its equity or debt securities. Except as set forth on Schedule 2.1(c) , the Company is not a party to, and it has no knowledge of, any agreement or understanding restricting the voting or transfer of any shares of the capital stock of the Company. Except as set forth on Schedule 8.18, the Company has not made any representations regarding equity incentives to any officer, employee, director or consultant that are not disclosed in the Public Filings.

(d)  Issuance of Securities . The Common Stock, Preferred Stock and Warrants to be issued at the Closing have been duly authorized by all necessary corporate action and, when paid for or issued in accordance with the terms hereof, such Common Stock, Preferred Stock and Warrants shall be validly issued and outstanding, fully paid and nonassessable, free and clear of all liens, encumbrances and rights of refusal of any kind. When the Subsequent Cashless Warrants, Preferred Stock issuable upon exercise of the Warrants and Conversion Shares are issued (following approval of the Authorized Share Increase), such Subsequent Cashless Warrants, Preferred Stock and Conversion Shares will be duly authorized by all necessary corporate action and validly issued and outstanding, fully paid and nonassessable, free and clear of all liens, encumbrances and rights of refusal of any kind. When the Conversion Shares are issued, the holders shall be entitled to all rights accorded to a holder of Common Stock. Each share of Preferred Stock shall have the rights, preferences, privileges and restrictions set forth in the Certificate of Designations. The certificates to be used to evidence the Preferred Stock will comply in all material respects with all applicable legal requirements, the requirements of the Company’s Certificate of Incorporation and the Certificate of Designations (collectively, the “ Certificate ”) and the Bylaws of the Company (the “ Bylaws ”).

(e)  No Conflicts . The execution, delivery and performance of the Transaction Documents by the Company and its Subsidiaries (as applicable), the performance by the Company of its obligations under the Warrants, and the consummation by the Company and its Subsidiaries of the transactions contemplated hereby and thereby, and the issuance of the Securities as contemplated hereby and thereby, do not and will not (i) violate or conflict with any provision of the Certificate or the Bylaws, each as amended to date, or any Subsidiary’s comparable charter documents, subject to the filing of an amendment to the Certificate to increase the authorized shares, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries’ respective properties or assets are bound, (iii) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries are bound or affected, or (iv) create or impose a lien, mortgage, security interest, charge or encumbrance of any nature on any property or asset of the Company or its Subsidiaries under any agreement or any commitment to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or by which any of their respective properties or assets are bound, except, in the case of clause (ii), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is required under federal, state, foreign or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under the Transaction Documents, issue and sell the Securities in accordance with the terms hereof (other than the filing of a Form D pursuant to Regulation D and counterpart filings under applicable state securities laws, rules or regulations). The business of the Company and its Subsidiaries is not being conducted in violation of any laws, ordinances or regulations of any governmental entity.

(f)  Authorization of Certificate of Designations . The Certificate of Designations, Preferences and Rights of Series C-1 Convertible Preferred Stock, Series C-2 Convertible Preferred Stock, Series D-1 Convertible Preferred Stock and Series D-2 Convertible Preferred Stock of La Jolla Pharmaceutical Company, substantially in the form attached hereto as Exhibit E (the “ Certificate of Designations ”), has been duly and validly authorized by the Company and, when filed by the Company with the Secretary of State of the State of Delaware, will be legally valid and effective and enforceable against the Company in accordance with its terms.

(g)  Commission Documents, Financial Statements . The Common Stock of the Company is registered pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and, since January 1, 2009, the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Exchange Act (all of the foregoing including filings incorporated by reference therein being referred to herein as the “ Commission Documents ”). At the times of their respective filings, the Form 10-K for the fiscal year ended December 31, 2009 (the “ Form 10-K ”) and any other report, schedule, form, statement or other document filed by the Company with the SEC pursuant to the reporting requirements of the Exchange Act subsequent to December 31, 2009 and prior to the Closing Date (collectively with the Form 10-K, the “ Public Filings ”) complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder and other federal, state and local laws, rules and regulations applicable to such documents, and the Public Filings did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the Commission Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles (“ GAAP ”) applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the financial position of the Company and its Subsidiaries as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).

(h)  Subsidiaries . Schedule 2.1(h) hereto sets forth each Subsidiary of the Company, showing the jurisdiction of its incorporation or organization and showing the percentage of each person’s ownership of the outstanding stock or other interests of such Subsidiary. For the purposes of this Agreement, “ Subsidiary ” shall mean any corporation or other entity of which at least a majority of the securities or other ownership interest having ordinary voting power (absolutely or contingently) for the election of directors or other persons performing similar functions are at the time owned directly or indirectly by the Company and/or any of its other Subsidiaries. All of the outstanding shares of capital stock of each Subsidiary have been duly authorized and validly issued, and are fully paid and nonassessable. Except as set forth on Schedule 2.1(h) hereto, there are no outstanding preemptive, conversion or other rights, options, warrants or agreements granted or issued by or binding upon any Subsidiary for the purchase or acquisition of any shares of capital stock of any Subsidiary or any other securities convertible into, exchangeable for or evidencing the rights to subscribe for any shares of such capital stock. Neither the Company nor any Subsidiary is subject to any obligation (contingent or otherwise) to repurchase or otherwise acquire or retire any shares of the capital stock of any Subsidiary or any convertible securities, rights, warrants or options of the type described in the preceding sentence except as set forth on Schedule 2.1(h) hereto. Neither the Company nor any Subsidiary is party to, nor has any knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of any Subsidiary. None of the Subsidiaries owns any assets or conduct any operations.

(i)  No Material Adverse Change . Since December 31, 2009, the Company has not experienced or suffered any Material Adverse Effect, except as disclosed on Schedule 2.1(i) hereto.

(j)  No Undisclosed Liabilities . Since December 31, 2009, except as disclosed on Schedule 2.1(j) hereto, neither the Company nor any of its Subsidiaries has incurred any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) other than those incurred in the ordinary course of the Company’s or its Subsidiaries’ respective businesses or which, individually or in the aggregate, are not reasonably likely to have a Material Adverse Effect.

(k)  No Undisclosed Events or Circumstances . Since December 31, 2009, except as disclosed on Schedule 2.1(k) hereto, no event or circumstance has occurred or exists with respect to the Company or its Subsidiaries or their respective businesses, properties, prospects, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed.

(l)  Indebtedness . Schedule 2.1(l) hereto sets forth as of the Closing Date all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “ Indebtedness ” shall include, without limitation, (a) any liabilities for borrowed money; (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of others, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) all leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

(m)  Title to Assets . Each of the Company and the Subsidiaries has good and valid title to all of its real and personal property reflected in the Public Filings, free and clear of any mortgages, pledges, charges, liens, security interests or other encumbrances, except for those indicated on Schedule 2.1(m) hereto or such that, individually or in the aggregate, do not cause a Material Adverse Effect. Any leases of the Company and each of its Subsidiaries are valid and subsisting and in full force and effect.

(n)  Actions Pending . There is no action, suit, claim, investigation, arbitration, alternate dispute resolution proceeding or other proceeding pending or, to the knowledge of the Company, threatened against the Company or any Subsidiary which questions the validity of this Agreement or any of the other Transaction Documents or any of the transactions contemplated hereby or thereby or any action taken or to be taken pursuant hereto or thereto. Except as set forth in the Public Filings or on Schedule 2.1(n) hereto, there is no action, suit, claim, investigation, arbitration, alternate dispute resolution proceeding or other proceeding pending or, to the knowledge of the Company, threatened against or involving the Company, any Subsidiary or any of their respective properties or assets, which individually or in the aggregate, would reasonably be expected, if adversely determined, to have a Material Adverse Effect. There are no outstanding orders, judgments, injunctions, awards or decrees of any court, arbitrator or governmental or regulatory body against the Company or any Subsidiary or any officers or directors of the Company or Subsidiary in their capacities as such, which individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.

(o)  Compliance with Law . The Company and its Subsidiaries have been and are presently conducting their respective businesses in accordance with all applicable federal, state and local governmental laws, rules, regulations and ordinances, except such that, individually or in the aggregate, the noncompliance therewith could not reasonably be expected to have a Material Adverse Effect. The Company and each of its Subsidiaries have all franchises, permits, licenses, consents and other governmental or regulatory authorizations and approvals necessary for the conduct of its business as now being conducted by it unless the failure to possess such franchises, permits, licenses, consents and other governmental or regulatory authorizations and approvals, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect.

(p)  Taxes . The Company and each of the Subsidiaries has accurately prepared and filed all federal, state and other tax returns required by law to be filed by it, has paid or made provisions for the payment of all taxes shown to be due and all additional assessments, and adequate provisions have been and are reflected in the financial statements of the Company and the Subsidiaries for all current taxes and other charges to which the Company or any Subsidiary is subject and which are not currently due and payable. Except as disclosed on Schedule 2.1(p) hereto or in the Public Filings, to the Company’s knowledge, none of the federal income tax returns of the Company or any Subsidiary have been audited by the Internal Revenue Service. Except as disclosed on Schedule 2.1(p) hereto or in the Public Filings, the Company has no knowledge of any additional assessments, adjustments or contingent tax liability (whether federal or state) of any nature whatsoever, whether pending or threatened against the Company or any Subsidiary for any period, nor of any basis for any such assessment, adjustment or contingency.

(q)  Certain Fees . Except as set forth on Schedule 2.1(q) hereto, the Company has not employed any broker or finder or incurred any liability for any brokerage or investment banking fees, commissions, finders’ structuring fees, financial advisory fees or other similar fees in connection with the Transaction Documents.

(r)  Disclosure . Except for the information concerning the transactions contemplated by this Agreement, the Company confirms that neither it nor any other person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that constitutes or might constitute material, nonpublic information. To the Company’s knowledge, neither this Agreement or the Schedules hereto nor any other documents, certificates or instruments furnished to the Purchasers by or on behalf of the Company or any Subsidiary in connection with the transactions contemplated by this Agreement contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made herein or therein, in the light of the circumstances under which they were made herein or therein, not misleading.

(s)  Environmental Compliance . To the Company’s knowledge, the Company and each of its Subsidiaries are in compliance with all limitations, restrictions, conditions, standards, requirements, schedules and timetables required or imposed under all applicable Environmental Laws. “ Environmental Laws ” shall mean all applicable laws relating to the protection of the environment including, without limitation, all requirements pertaining to reporting, licensing, permitting, controlling, investigating or remediating emissions, discharges, releases or threatened releases of hazardous substances, chemical substances, pollutants, contaminants or toxic substances, materials or wastes, whether solid, liquid or gaseous in nature, into the air, surface water, groundwater or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of hazardous substances, chemical substances, pollutants, contaminants or toxic substances, material or wastes, whether solid, liquid or gaseous in nature. Except for such instances as would not individually or in the aggregate have a Material Adverse Effect, there are, to the knowledge of the Company, no past or present events, conditions, circumstances, incidents, actions or omissions by or on the part of the Company or its Subsidiaries that violate or may violate any Environmental Law after the Closing Date or that may give rise to any environmental liability, or otherwise form the basis of any claim, action, demand, suit, proceeding, hearing, study or investigation (i) under any Environmental Law, or (ii) based on or related to the manufacture, processing, distribution, use, treatment, storage (including without limitation underground storage tanks), disposal, transport or handling, or the emission, discharge, release or threatened release of any hazardous substance.

(t)  Books and Records; Internal Accounting Controls . The records and documents of the Company and its Subsidiaries accurately reflect in all material respects the information relating to the business of the Company and the Subsidiaries, the location and collection of their assets, and the nature of all transactions giving rise to the obligations or accounts receivable of the Company or any Subsidiary. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. The Company and its Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by the Company’s most recently filed periodic report under the Exchange Act (such date, the “ Evaluation Date ”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the Company’s internal control over financial reporting (as such term is defined in the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

(u)  Material Agreements . Except as disclosed in the Public Filings or as set forth on Schedule 2.1(u) hereto, or as would not be reasonably likely to have a Material Adverse Effect, (i) the Company and each of its Subsidiaries have performed all obligations required to be performed by them to date under any written or oral contract, instrument, agreement, commitment, obligation, plan or arrangement, filed or required to be filed with the SEC (the “ Material Agreements ”), (ii) neither the Company nor any of its Subsidiaries has received any notice of default under any Material Agreement which has not since been cured or settled and, (iii) to the Company’s knowledge, neither the Company nor any of its Subsidiaries is in default under any Material Agreement now in effect.

(v)  Transactions with Affiliates . Except as set forth on Schedule 2.1(v) hereto or in the Public Filings and otherwise contemplated by this Agreement, there are no loans, leases, agreements, contracts, royalty agreements, management contracts or arrangements or other continuing transactions between (a) the Company, any Subsidiary or any of their respective customers or suppliers on the one hand, and (b) on the other hand, any officer, employee, consultant or director of the Company, or any of its Subsidiaries, or any person owning at least 5% of the outstanding capital stock of the Company or any Subsidiary or any member of the immediate family of such officer, employee, consultant, director or stockholder or any corporation or other entity controlled by such officer, employee, consultant, director or stockholder, or a member of the immediate family of such officer, employee, consultant, director or stockholder which, in each case, is required to be disclosed in the Commission Documents or in the Company’s most recently filed definitive proxy statement on Schedule 14A, that is not so disclosed in the Commission Documents or in such proxy statement.

(w)  Securities Act of 1933 . The Company has complied and will comply with all applicable federal and state securities laws in connection with the offer, issuance and sale of the Securities hereunder. Neither the Company nor anyone acting on its behalf, directly or indirectly, has or will sell, offer to sell or solicit offers to buy any of the Securities or similar securities to, or solicit offers with respect thereto from, or enter into any negotiations relating thereto with, any person, or has taken or will take any action so as to bring the issuance and sale of any of the Securities under the registration provisions of the Securities Act and applicable state securities laws, and neither the Company nor any of its affiliates, nor any person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of any of the Securities.

(x)  Employees . Neither the Company nor any Subsidiary has any collective bargaining arrangements or agreements covering any of its employees, except as set forth on Schedule 2.1(x) hereto. Except as set forth on Schedule 2.1(x) hereto or in the Public Filings, neither the Company nor any Subsidiary has any employment contract, agreement regarding proprietary information, non-competition agreement, non-solicitation agreement, confidentiality agreement, or any other similar contract or restrictive covenant, relating to the right of any officer, employee or consultant to be employed or engaged by the Company or such Subsidiary required to be disclosed in the Commission Documents that is not so disclosed. No officer, consultant or key employee of the Company or any Subsidiary whose termination, either individually or in the aggregate, would be reasonably likely to have a Material Adverse Effect, has terminated or, to the knowledge of the Company, has any present intention of terminating his or her employment or engagement with the Company or any Subsidiary.

(y)  Absence of Certain Developments . Except as set forth in the Public Filings or provided on Schedule 2.1(y) hereto or as otherwise contemplated by this Agreement, since December 31, 2009, neither the Company nor any Subsidiary has:

(i)  issued any stock, bonds or other corporate securities or any right, options or warrants with respect thereto;

(ii)  borrowed any amount in excess of $50,000 or incurred or become subject to any other liabilities in excess of $50,000 (absolute or contingent) except current liabilities incurred in the ordinary course of business which are comparable in nature and amount to the current liabilities incurred in the ordinary course of business during the comparable portion of its prior fiscal year, as adjusted to reflect the current nature and volume of the business of the Company and its Subsidiaries;

(iii)  discharged or satisfied any lien or encumbrance in excess of $50,000 or paid any obligation or liability (absolute or contingent) in excess of $50,000, other than current liabilities paid in the ordinary course of business;

(iv)  declared or made any payment or distribution of cash or other property to stockholders with respect to its stock, or purchased or redeemed, or made any agreements so to purchase or redeem, any shares of its capital stock, in each case in excess of $5,000 individually or $10,000 in the aggregate;

(v)  sold, assigned or transferred any other tangible assets, or canceled any debts or claims, in each case in excess of $50,000, except in the ordinary course of business;

(vi)  sold, assigned or transferred any patent rights, trademarks, trade names, copyrights, trade secrets or other intangible assets or intellectual property rights in excess of $50,000, or disclosed any proprietary confidential information to any person except to customers in the ordinary course of business or to the Purchasers or their representatives;

(vii)  suffered any material losses or waived any rights of material value, whether or not in the ordinary course of business, or suffered the loss of any material amount of prospective business;

(viii)  made any changes in employee compensation except in the ordinary course of business and consistent with past practices;

(ix)  made capital expenditures or commitments therefor that aggregate in excess of $50,000;

(x)  entered into any material transaction, whether or not in the ordinary course of business;

(xi)  made charitable contributions or pledges in excess of $10,000;

(xii)  suffered any material damage, destruction or casualty loss, whether or not covered by insurance;

(xiii)  experienced any material problems with labor or management in connection with the terms and conditions of their employment; or

(xiv)  entered into an agreement, written or otherwise, to take any of the foregoing actions.

(z)  Investment Company Act Status . The Company is not, and as a result of and immediately upon the Closing will not be, an “investment company” or a company “controlled” by an “investment company,” within the meaning of the Investment Company Act of 1940, as amended.

(aa)  Independent Nature of Purchasers . The Company acknowledges that the obligations of each Purchaser under the Transaction Documents are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under the Transaction Documents. The Company acknowledges that the decision of each Purchaser to purchase Securities pursuant to this Agreement has been made by such Purchaser independently of any other purchase and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company or of its Subsidiaries which may have made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no Purchaser or any of its agents or employees shall have any liability to any Purchaser (or any other person) relating to or arising from any such information, materials, statements or opinions. The Company acknowledges that nothing contained herein, or in any Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. The Company acknowledges that for reasons of administrative convenience only, the Transaction Documents have been prepared by counsel for one of the Purchasers and such counsel does not represent all of the Purchasers but only such Purchaser and the other Purchasers have retained their own individual counsel with respect to the transactions contemplated hereby. The Company acknowledges that it has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by the Purchasers. The Company acknowledges that such procedure with respect to the Transaction Documents in no way creates a presumption that the Purchasers are in any way acting in concert or as a group with respect to the Transaction Documents or the transactions contemplated hereby or thereby. The Company acknowledges that each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.

(bb)  No Integrated Offering . Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offering of the Securities pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of the Securities Act which would prevent the Company from selling the Securities pursuant to Regulation D and Rule 506 thereof under the Securities Act nor will the Company or any of its affiliates or subsidiaries take any action or steps that would cause the offering of the Securities to be integrated with other offerings if to do so would prevent the Company from selling Securities pursuant to Regulation D and Rule 506 thereof under the Securities Act or otherwise prevent a completed offering of Securities hereunder. Except as set forth on Schedule 2.1(bb) hereto, the Company does not have any registration statement pending before the SEC or currently under the SEC’s review and since December 31, 2009, the Company has not offered or sold any of its equity securities or debt securities convertible into shares of Common Stock.

(cc)  Dilutive Effect . The Company understands and acknowledges that its obligation to issue Conversion Shares in accordance with this Agreement and the Preferred Stock is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interest of other stockholders of the Company.

(dd)  DTC Status . Except as set forth on Schedule 2.1(dd) hereto, the Company’s transfer agent is a participant in and the Common Stock is eligible for transfer pursuant to the Depository Trust Company Automated Securities Transfer Program. The name, address, telephone number, fax number, contact person and email of the Company transfer agent is set forth on Schedule 2.1(dd) hereto.

(ee)  Governmental Approvals . Except for (i) the filing of any notice prior or subsequent to the Closing that may be required under applicable state and/or federal securities laws (which if required, shall be filed on a timely basis), and (ii) required filings that must be made with the Delaware Secretary of State to give effect to the Reverse Splits and the Charter Amendment, no authorization, consent, approval, license, exemption of, filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, is or will be necessary for, or in connection with, the execution or delivery of the Conversion Shares, or for the performance by the Company of its obligations under the Transaction Documents.

(ff)  Insurance . The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

(gg)  Trading Activities. Except as set forth herein or in the Warrants, it is understood and acknowledged by the Company that none of the Purchasers have been asked to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified term. The Company further understands and acknowledges that one or more Purchasers may engage in hedging and/or trading activities at various times during the period that the Securities are outstanding and (b) such hedging and/or trading activities, if any, can reduce the value of the existing stockholders’ equity interest in the Company both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or trading activities, assuming such trading and hedging activities are in compliance with all applicable securities laws and subject to the representations and warranties set forth in Section 2.2(j), do not otherwise constitute a breach of this Agreement, the Warrants or any of the documents executed in connection herewith.

(hh)  Company Status . Since December 31, 2008, the Company has not been, and through the consummation of a Strategic Transaction (as defined in the Certificate of Designations), the Company will not be, a “shell company” or a “blank check company,” each as defined by the applicable rules and regulations of the SEC.

2.2 Representations and Warranties of the Purchasers . Each of the Purchasers hereby represents and warrants to the Company with respect solely to itself and not with respect to any other Purchaser as follows as of the date hereof and as of the Closing Date:

(a)  Organization and Standing of the Purchasers . If the Purchaser is an entity, such Purchaser is a corporation, limited liability company or partnership duly incorporated or organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization.

(b)  Authorization and Power . Each Purchaser has the requisite power and authority to enter into and perform the Transaction Documents and to purchase the Securities being sold to it hereunder. The execution, delivery and performance of the Transaction Documents by each Purchaser and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate or partnership action, and no further consent or authorization of such Purchaser or its Board of Directors, stockholders, or partners, as the case may be, is required. When executed and delivered by the Purchasers, the Transaction Documents shall constitute valid and binding obligations of each Purchaser enforceable against such Purchaser in accordance with their terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.

(c)  Acquisition for Investment . Each Purchaser is purchasing the Securities solely for its own account and not with a view to or for sale in connection with distribution. Each Purchaser does not have a present intention to sell any of the Securities, nor a present arrangement (whether or not legally binding) or intention to effect any distribution of any of the Securities to or through any person or entity; provided, however, that by making the representations herein, such Purchaser does not agree to hold the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with federal and state securities laws applicable to such disposition. Each Purchaser acknowledges that it (i) has such knowledge and experience in financial and business matters such that Purchaser is capable of evaluating the merits and risks of Purchaser’s investment in the Company, (ii) is able to bear the financial risks associated with an investment in the Securities and (iii) has been given full access to such records of the Company and the Subsidiaries and to the officers of the Company and the Subsidiaries as it has deemed necessary or appropriate to conduct its due diligence investigation.

(d)  Rule 144 . Each Purchaser understands that the Securities must be held indefinitely unless such Securities are registered under the Securities Act (recognizing that the Company has no obligation hereunder to effect such registration) or an exemption from registration is available. Each Purchaser acknowledges that such person is familiar with Rule 144 of the rules and regulations of the SEC, as amended, promulgated pursuant to the Securities Act (“ Rule 144 ”), and that such Purchaser has been advised that Rule 144 permits resales only under certain circumstances. Each Purchaser understands that to the extent that Rule 144 is not available, such Purchaser will be unable to sell any Securities without either registration under the Securities Act or the existence of another exemption from such registration requirement.

(e)  General . Each Purchaser understands that the Securities are being offered and sold in reliance on a transactional exemption from the registration requirements of federal and state securities laws and the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the applicability of such exemptions and the suitability of such Purchaser to acquire the Securities. Each Purchaser understands that no United States federal or state agency or any government or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

(f)  No General Solicitation . Each Purchaser acknowledges that the Securities were not offered to such Purchaser by means of any form of general or public solicitation or general advertising, or publicly disseminated advertisements or sales literature, including (i) any advertisement, article, notice or other communication published in any newspaper, magazine, or similar media, or broadcast over television or radio, or (ii) any seminar or meeting to which such Purchaser was invited by any of the foregoing means of communications. Each Purchaser, in making the decision to purchase the Securities, has relied upon independent investigation made by it and has not relied on any information or representations made by third parties, and was not solicited through any pending registration statement of the Company described on Schedule 2.1(bb).

(g)  Accredited Investor . Except as set forth on Schedule 2.2(g), each Purchaser is an “accredited investor” (as defined in Rule 501 of Regulation D), and such Purchaser has such experience in business and financial matters that it is capable of evaluating the merits and risks of an investment in the Securities. Such Purchaser is not required to be registered as a broker-dealer under Section 15 of the Exchange Act and such Purchaser is not a broker-dealer. Each Purchaser acknowledges that an investment in the Securities is speculative and involves a high degree of risk.

(h)  Certain Fees . The Purchasers have not employed any broker or finder or incurred any liability for any brokerage or investment banking fees, commissions, finders’ structuring fees, financial advisory fees or other similar fees in connection with the Transaction Documents.

(i)  Independent Investment . No Purchaser has agreed to act with any other Purchaser for the purpose of acquiring, holding, voting or disposing of the Securities purchased hereunder for purposes of Section 13(d) under the Exchange Act, and each Purchaser is acting independently with respect to its investment in the Securities.

(j)  No Short Sales . Commencing on the date that the Purchasers were initially contacted regarding an investment in the Securities, none of the Purchasers has engaged in any Short Sale (defined below) of the Common Stock and will not engage in any Short Sale of the Common Stock prior to public announcement of the transactions contemplated by this Agreement pursuant to Section 3.9, nor has any Short Sale been executed by or on behalf of the Purchaser during the period beginning 30 days before the date hereof.  For purposes of this Agreement, “Short Sale” means all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker-dealers or foreign regulated brokers, but only if executed at a time when the Purchaser has no equivalent offsetting long position in the common stock of the Company.

2.3 Outstanding Securities and Purchase Rights . Each Purchaser represents and warrants that as of the Closing, such Purchaser holds the Company securities in the principal amounts set forth on such Purchaser’s signature page hereto.

ARTICLE 3

COMPANY COVENANTS

Unless otherwise specified in this Article, for so long as any Preferred Stock or Warrants remain outstanding in whole or in part, the Company covenants with each Purchaser as follows, which covenants are for the benefit of each Purchaser and their respective permitted assignees.

3.1 Securities Compliance . The Company shall notify the SEC in accordance with its rules and regulations of the transactions contemplated by any of the Transaction Documents and shall take all other necessary action and proceedings as may be required by applicable law, rule and regulation, for the legal and valid issuance of the Securities to the Purchasers, or their respective subsequent holders.

3.2 Registration and Listing . The Company shall (a) cause its Common Stock to continue to be registered under Sections 12(b) or 12(g) of the Exchange Act, (b) comply in all respects with its reporting and filing obligations under the Exchange Act and (c) not take any action or file any document (whether or not permitted by the Securities Act or the rules promulgated thereunder) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under the Exchange Act or Securities Act. The Company will use reasonable best efforts to continue the listing or trading of its Common Stock on The OTC Bulletin Board or the Pink Sheets (as applicable, the “ Principal Market ”). The Company further covenants that it will take such further action as the Purchasers may reasonably request from time to time to enable the Purchasers to sell the Securities without registration under the Securities Act pursuant to the exemption provided by Rule 144, provided that the Company shall not be required to consent to the service of process in any jurisdiction in connection with any such request. Upon the request of the Purchasers, the Company shall deliver to the Purchasers a written certification of a duly authorized officer as to whether it has complied with such requirements .

3.3 Compliance with Laws . The Company shall comply, and cause each Subsidiary to comply, with all applicable laws, rules, regulations and orders, noncompliance with which would be reasonably likely to have a Material Adverse Effect.

3.4 Keeping of Records and Books of Account . The Company shall keep and cause each Subsidiary to keep adequate records and books of account, in which complete entries will be made in accordance with GAAP consistently applied, (a) reflecting all financial transactions of the Company and its Subsidiaries, and (b) for each fiscal year, all proper reserves for depreciation, depletion, obsolescence, amortization, taxes, bad debts and other purposes in connection with its business.

3.5 Reporting Requirements . If the Company ceases to file its periodic reports with the SEC, or if the SEC and the Company both cease making these periodic reports available via the Internet without charge, then, in addition to any other remedies that the Purchasers may have, the Company shall, upon the written request of a Purchaser, furnish the following to each Purchaser so long as such Purchaser shall be obligated hereunder to purchase the Securities or shall beneficially own Securities:

(a)  Quarterly Reports on Form 10-Q (or an equivalent form), including financial statements, (i) promptly following the end of each quarter, and in any event within 45 days of the end of each quarter (or such longer period of time as would have been allowed under Rule 12b-25 under the Exchange Act), if such reports are no longer filed with the SEC or (ii) as soon as practical after the document is filed with the SEC, and in any event within five days after the document is filed with the SEC;

(b)  Annual Reports on Form 10-K (or an equivalent form), including financial statements, (i) promptly following the end of each year, and in any event within 90 days of the end of each year (or such longer period of time as would have been allowed under Rule 12b-25 under the Exchange Act), if such reports are no longer filed with the SEC or (ii) as soon as practical after the document is filed with the SEC, and in any event within five days after the document is filed with the SEC; and

(c)  Copies of all notices, information and proxy statements in connection with any meetings, that are, in each case, provided to holders of shares of Common Stock, contemporaneously with the delivery of such notices or information to such holders of Common Stock.

3.6 Other Agreements . The Company shall not enter into any agreement in which the terms of such agreement would be reasonably expected to restrict or impair the right or ability of the Company or any Subsidiary to perform under any Transaction Document.

3.7 Use of Proceeds; Net Cash Schedules . So long as (i) at least 1,000 shares of Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares) are outstanding and (ii) no Strategic Transaction has been consummated:

(a)  The proceeds from the sale of the Securities hereunder shall be used by the Company for general corporate purposes in accordance with the Net Cash Schedules (as defined below) and the Company shall not make any payment, or incur any obligation or liability that may be settled in cash, that causes the balance of the Net Cash (as defined in Section 3.7(c)(i)) as of any date set forth in the most recently approved Net Cash Schedule to be less than the Net Cash reflected for such date on such Net Cash Schedule.

(b)  Other than redemptions of unvested Common Stock issued pursuant to equity compensation plans or agreements, in no event shall the proceeds be used to redeem any Common Stock or securities convertible, exercisable or exchangeable into Common Stock (other than the Preferred Stock) or to settle any outstanding litigation.

(c)  The Company shall manage and periodically report its Net Cash as follows:

(i)  For a period of six months from the Closing Date (the “ Disclosure Period ”), the Company shall send to the Purchasers within 15 calendar days of the end of each month during the Disclosure Period, subject to each such Purchaser’s agreement to hold such information in strict confidence and to not trade in Company securities on the basis of such information, a statement showing the amount, as of the end of each such calendar month, determined according to the following formula (such amount, the “ Net Cash ”): (i) the sum of the Company’s unrestricted, consolidated (x) cash, (y) cash equivalents and (z) short term investments, available for sale, less (ii) the amount of the Company’s liabilities that may be settled in cash, including any off-balance sheet obligations that may be settled in cash;

(ii)  On or prior to the last day of the Disclosure Period, the Company shall file with the SEC a Form 8-K or Form 10-Q disclosing: (i) the Initial Net Cash Schedule (as defined in Section 5.2(n) below) for each calendar month commencing with October 2010 through March 2011 and (ii) the Net Cash balance as of September 30, 2010; and

(iii)  Following the expiration of the Disclosure Period, the Company shall:

(1)  In each of the Company’s annual reports on Form 10-K, disclose a schedule showing, as of the end of each of the twelve (12) calendar months April through March following the filing of such Form 10-K (commencing with April 2011 to March 2012), the Company’s anticipated Net Cash balance for such dates (the “ Subsequent Net Cash Schedules ” and, together with the Initial Net Cash Schedule, each, a “ Net Cash Schedule ”);

(2)  In each quarterly or annual report on Form 10-Q or Form 10-K, report its Net Cash as of the end of the latest quarter covered by such report; and

(3)  In the event that the Company’s Net Cash as of the end of a calendar month is less than the corresponding amount set forth in the applicable Net Cash Schedule, then the Company shall, within 15 calendar days following the end of such calendar month (or 30 calendar days if it is the last month of a fiscal year) file a Current Report on Form 8-K disclosing the amount of such variance and the actual Net Cash balance of the Company as of such date.

(iv)  Each Subsequent Net Cash Schedule must be approved, in writing, by the Requisite Holders prior to its disclosure. The Company shall deliver to the Purchasers written notice at least one Week prior to the delivery of any Subsequent Cash Schedule to the Purchasers for approval pursuant to this section notifying the Purchasers of the expected date of such delivery. The Company shall publicly disclose each approved Subsequent Net Cash Schedule through a Current Report on Form 8-K, Annual Report on Form 10-K or Quarterly Report on Form 10-Q, in each case no later than two (2) Trading Days (as defined in the Certificate of Designations) following the approval of such Subsequent Net Cash Schedule.

3.8 Reporting Status . So long as a Purchaser beneficially owns any of the Securities, the Company shall timely file all reports required to be filed with the SEC pursuant to the Exchange Act, and the Company shall not terminate its status as an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would permit such termination.

3.9 Disclosure of Transaction . The Company shall issue a press release describing the material terms of the transactions contemplated hereby (the “ Press Release ”) no later than 9:00 A.M. Eastern Time on the first Trading Day following the effective date of this Agreement. The Company shall also file with the SEC a Form 8-K describing the material terms of the transactions contemplated hereby as soon as practicable following the effective date of this Agreement but in no event more than the fourth Trading Day following the effective date of this Agreement, which Press Release and Form 8-K shall be subject to prior review and approval by the Lead Purchaser (as defined in Section 8.15 below).

3.10 Disclosure of Material Information . Except with respect to information that may be provided during the Disclosure Period or information disclosed to any Purchaser who is also an officer, director or employee of the Company, the Company covenants and agrees that neither it nor any other person acting on its behalf has provided or will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of and specifically identifying such information as material and non-public. The Company understands and confirms that each Purchaser shall be relying on the foregoing representations in effecting transactions in securities of the Company. In the event of a breach of the foregoing covenant by the Company, or any of its Subsidiaries, or any of its or their respective officers, directors, employees and agents, in addition to any other remedy provided herein or in the Transaction Documents, the Company shall notify the Purchasers immediately upon learning of such breach and thereafter publicly disclose any material, non-public information in a Form 8-K within one business day of the date that it discloses such information to any Purchaser. In the event that the Company discloses any material, non-public information to a Purchaser in violation of this Section 3.10 and fails to publicly file a Form 8-K in accordance with the above, a Purchaser shall have the right, upon providing the Company with 48 hours prior written notice, to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information without the prior approval by the Company, its Subsidiaries, or any of its or their respective officers, directors, employees or agents. No Purchaser shall have any liability to the Company, its Subsidiaries, or any of its or their respective officers, directors, employees, stockholders or agents, for any such disclosure in connection with which such Purchaser has complied with this Section 3.10 and the Company has failed to act as required under this Section 3.10.

3.11 Pledge of Securities . The Company acknowledges that the Securities may be pledged by a Purchaser in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Purchaser effecting a pledge of the Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document; provided that a Purchaser and its pledgee shall be required to comply with the provisions of Article 6 hereof in order to effect a sale, transfer or assignment of Securities to such pledgee. At the Purchasers’ expense, the Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by a Purchaser.

3.12 Other Covenants . For so long as at least 1,000 shares of Preferred Stock, or at least 3,000 shares of Preferred Stock if all Cash Warrants have been fully exercised, are outstanding, the Company shall:

(a)  maintain, and cause each of its Subsidiaries to maintain insurance with responsible and reputable insurance companies or associations (including comprehensive general liability) with respect to its properties (including all real properties leased or owned by it) and business, in such amounts and covering such risks as is (i) required by any governmental authority having jurisdiction with respect thereto and (ii) as is carried generally in accordance with sound business practice by companies in similar businesses similarly situated;

(b)  not, without the prior approval (by vote or by written consent, as provided in the Delaware General Corporation Law) of the Requisite Holders, transfer any assets to any Subsidiary or to otherwise cause any Subsidiary to acquire any assets or commence operations;

(c)  not, without the prior approval (by vote or by written consent, as provided in the Delaware General Corporation Law) of the Requisite Holders, take any of the actions enumerated in Article XII of the Certificate of Designations (whether by merger, consolidation, conversion or otherwise); and

(d)  provided the same would not be in violation of Regulation FD, permit, during normal business hours and upon reasonable request and reasonable notice, each Purchaser or any employees, agents or representatives thereof, so long as such Purchaser shall be obligated hereunder to purchase the Securities or shall beneficially own any Conversion Shares, for purposes reasonably related to such Purchaser’s interests as a stockholder, to visit the Company to discuss the publicly available, non-confidential affairs, finances and accounts of the Company and any Subsidiary with any of its executive officers.

ARTICLE 4
PURCHASER COVENANTS

4.1 Unless otherwise specified in this Article, for so long as any Preferred Stock or Warrants remain outstanding in whole or in part, each Purchaser covenants with the Company as follows, which covenants are for the benefit of the Company and its permitted assignees.

(a)  Transfer Restrictions on Series C-1 Preferred, Cashless Warrants and Series D-1 Preferred . The Series C-1 Preferred, Cashless Warrants and Series D-1 Preferred, and all rights thereunder, shall not be sold or transferred prior to the date that is six months and forty-one (41) Weeks following the Closing Date. Any purported sale or transfer effected in violation of this Section 4.1(a) shall be null and void.

(b)  Transfer Restrictions on Series C-2 Preferred, Cash Warrants, Subsequent Cashless Warrants and Series D-2 Preferred . The Series C-2 preferred, Cash Warrants, Subsequent Cashless Warrants and Series D-2 Preferred, and all rights thereunder, shall not be sold or transferred prior to the date that is six months and forty (40) Weeks following, with respect to a particular Purchaser, the first date of exercise, in whole or part, of the Cash Warrant held by such Purchaser. Any purported sale or transfer effected in violation of this Section 4.1(b) shall be null and void.

(c)  Conversion Limitations . For so long as any Securities remain outstanding, each Purchaser covenants and agrees that it will not convert any Securities into Common Stock in contravention of Article IV.C. of the Certificate of Designations.

4.2 Each Purchaser covenants that the Securities shall only be disposed pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in compliance with any applicable state and federal securities laws.

4.3 Upon the consummation of an approved Strategic Transaction, each Purchaser shall exercise the Cash Warrant in full within the time period and in the manner set forth in Section 1(d) of the Cash Warrant. If a Purchaser fails to timely exercise the Cash Warrant (such purchaser, a “ Defaulting Purchaser ”), interest shall thereafter accrue on the sums due to the Company under such Cash Warrant at a rate equal to the lesser of 18% per annum and the highest interest rate permitted by applicable law. Additionally, until such Cash Warrant is exercised in full:

(a)  all covenants and obligations owed by the Company to such Defaulting Purchaser under the Transaction Documents shall be suspended until such Cash Warrant is exercised in full, and all defaults by the Company under the Transaction Documents shall, solely with respect to the Defaulting Purchaser, be deemed irrevocably waived by such Defaulting Purchaser; and

(b)  the Defaulting Purchaser shall be required to pay the Company (i) on the consummation of the Strategic Transaction and (ii) on the last day of each Week elapsed following the consummation of the Strategic Transaction until the Cash Warrant is exercised in full, a cash payment in an amount, in each instance set forth in clauses (i) and (ii), equal to three percent (3%) of the aggregate exercise price for such Cash Warrant.

For clarification, the remedies set forth in Section 4.3 shall apply only with respect to the particular Defaulting Purchaser and not to any other Purchaser and shall not affect the voting rights of the Defaulting Purchaser under the Transaction Documents or the Certificate of Designations.

ARTICLE 5

CONDITIONS

5.1 Conditions Precedent to the Obligation of the Company to Close and to Sell the Securities . The obligation hereunder of the Company to close and issue and sell the Securities to the Purchasers at the Closing is subject to the satisfaction or waiver, at or before the Closing, of the conditions set forth below. These conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion.

(a)  Accuracy of the Purchasers’ Representations and Warranties . The representations and warranties of each Purchaser shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and correct in all material respects as of such date.

(b)  Performance by the Purchasers . Each Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchasers at or prior to the Closing Date.

(c)  No Injunction . No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement or any other Transaction Document.

(d)  Delivery of Purchase Price . The Purchase Price for the Securities shall have been delivered to the Company on or before the Closing Date.

(e)  Delivery of Transaction Documents . The Transaction Documents shall have been duly executed and delivered by the Purchasers to the Company.

(f)  Letter Agreement . The letter agreement in substantially the form attached hereto as Exhibit G shall have been signed by the Purchasers identified therein and delivered to the Company.

5.2 Conditions Precedent to the Obligation of the Purchasers to Close and to Purchase the Securities . The obligation hereunder of the Purchasers to purchase the Securities and consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver, at or before the Closing, of each of the conditions set forth below. These conditions are for the Purchasers’ sole benefit and may be waived by the Requisite Holders at any time in their sole discretion.

(a)  Accuracy of the Company’s Representations and Warranties . Each of the representations and warranties of the Company and its Subsidiaries in this Agreement and the other Transaction Documents shall be true and correct in all material respects as of the Closing Date, except for representations and warranties that speak as of a particular date, which shall be true and correct in all material respects as of such date.

(b)  Performance by the Company and Subsidiaries . Each of the Company and its Subsidiaries shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company and its Subsidiaries at or prior to the Closing Date.

(c)  No Suspension, Etc. The shares of Common Stock: (i) shall be designated for quotation or listed on the Principal Market and (ii) shall not have been suspended, as of the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or the Principal Market have been threatened, as of the Closing Date, either (A) in writing by the SEC or the Principal Market or (B) by falling below the minimum listing maintenance requirements of the Principal Market.

(d)  No Injunction . No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement or any other Transaction Document.

(e)  No Proceedings or Litigation . No action, suit or proceeding before any arbitrator or any governmental authority shall have been commenced, and no investigation by any governmental authority shall have been threatened, against the Company or any Subsidiary, or any of the officers, directors or affiliates of the Company or any Subsidiary which, in either such case, (i) seeks to restrain, prevent or change the transactions contemplated by this Agreement, or (ii) seeks damages in connection with such transactions.

(f)  Opinion of Counsel . The Purchasers shall have received an opinion of counsel to the Company, dated the date of the Closing Date, substantially in the form of Exhibit H hereto, with such exceptions and limitations as shall be reasonably acceptable to counsel to the Purchasers.

(g)  Common Stock, Series C-1 Preferred Stock and Warrants . At or prior to the Closing, the Company shall have delivered to the Purchasers the Series C-1 Preferred Stock, Cash Warrants and Cashless Warrants and shall have arranged for the Company’s transfer agent to electronically deliver to the Purchasers the Common Stock to be held in street name, in each case in accordance with the terms of this Agreement.

(h)  Secretary’s Certificate . The Company and each Subsidiary of the Company shall have delivered to the Purchasers a secretary’s certificate, dated as of the Closing Date, as to (i) the resolutions adopted by its Board of Directors approving the transactions contemplated hereby, (ii) its certificate of incorporation, (iii) its bylaws, each as in effect at the Closing Date, and (iv) the authority and incumbency of the officers executing the Transaction Documents and any other documents required to be executed or delivered in connection therewith.

(i)  Officer’s Certificate . On the Closing Date, the Company and each Subsidiary shall have delivered to the Purchasers a certificate signed by an executive officer on behalf of the Company and each Subsidiary, dated as of the Closing Date, confirming the accuracy of the Company’s and each Subsidiary’s representations, warranties and covenants as of the Closing Date and confirming the compliance by the Company with the conditions precedent set forth in paragraphs (a)-(e) and (j) of this Section 5.2 as of the Closing Date (provided that, with respect to the matters in paragraphs (d) and (e) of this Section 5.2, such confirmation shall be based on the knowledge of the executive officer after due inquiry).

(j)  Material Adverse Effect . No Material Adverse Effect shall have occurred.

(k)  Change in Purchasers . There shall have been no changes to Exhibit A (List of Purchasers) since the execution of this Agreement.

(l)  Delivery of Transaction Documents . Each of the Transaction Documents to which the Company is a party shall have been duly executed and delivered by the Company to the Purchasers.

(m)  Filing of Certificate of Designation. The Certificate of Designations shall have been adopted and approved by the Company’s Board of Directors as required by applicable law (including without limitation the Delaware General Corporation Law), the Certificate and Bylaws and any agreements to which the Company is a party or is bound, and the Company shall have filed the Certificate of Designations with the Secretary of State of the State of Delaware who shall have accepted the Certificate of Designations for filing, and the Certificate of Designations shall be in full force and effect as of the Closing.

(n)  Delivery of Initial Cash Schedule . Exhibit F attached hereto contains a schedule showing, as of the last day of each calendar month commencing with May 2010 and continuing through March 2011 the Company’s anticipated Net Cash balance for such dates (the “ Initial Net Cash Schedule ”).

ARTICLE 6

CERTIFICATE LEGENDS

6.1 Legends . Except as set forth herein, each certificate representing shares of Preferred Stock shall be stamped or otherwise imprinted with legends substantially in the following form (in addition to any legend required by applicable state securities or “blue sky” laws):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS EITHER (A) REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR (B) THE COMPANY HAS RECEIVED A REASONABLY ACCEPTABLE OPINION OF COUNSEL STATING THAT THE REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED FOR SUCH SALE, TRANSFER OR OTHER DISPOSITION.

THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN SECURITIES PURCHASE AGREEMENT BY AND AMONG THE CORPORATION AND CERTAIN ORIGINAL PURCHASERS OF THESE SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION.

The Company agrees to issue or reissue certificates representing any of the Conversion Shares without legends if, in the case of any holder or acquiror of such Conversion Shares (x) the Conversion Shares can be sold by such holder pursuant to Rule 144 without any restriction as to the number of securities or (y) the holder is selling such Conversion Shares in compliance with the provisions of Rule 144. In addition, if the Company’s transfer agent is participating in a program, including without limitation the Depository Trust Company (“ DTC ”) Fast Automated Securities Transfer program or any equivalent program, that permits the transfer agent to electronically transmit the Conversion Shares, and if the Conversion Shares can then be sold pursuant to Rule 144 without any restriction as to the number of securities, then in such case the Company shall cause its transfer agent, by the end of the Delivery Period (as defined in the Certificate of Designations), to electronically transmit the Conversion Shares (not in physical certificate form), without legends, to the holder, by crediting the account of the holder or its nominee with DTC through the Deposit Withdrawal Agent Commission system or through such other equivalent program. In connection with the issuance of the Conversion Shares as set forth herein, each Purchaser acknowledges that the Company is relying on the representations and warranties of such Purchaser set forth in Section 2.2 and the covenants of such Purchaser set forth in Section 4.2.

6.2 Purchaser Indemnity . Each Purchaser shall severally, but not jointly, indemnify, defend and hold harmless the Company (and its directors, officers, affiliates, employees, agents, successors and assigns) (each a “ Company Indemnified Party ”) from and against any and all losses, liabilities, deficiencies, costs, damages and expenses (including, without limitation, reasonable attorneys’ fees, charges and disbursements) incurred by any Company Indemnified Party as a result of claims brought by third parties arising out of or relating to any breach of the covenants made by such Purchaser in Section 4.2. In the event that a Company Indemnified Party shall seek indemnification under this Section 6.2, the provisions of Section 7.2 ( mutatis mutandis ) shall apply to any such claim.

ARTICLE 7

INDEMNIFICATION

7.1 General Indemnity . The Company agrees to indemnify and hold harmless the Purchasers (and their respective directors, officers, affiliates, members, managers, employees, agents, successors and assigns) from and against any and all losses, liabilities, deficiencies, costs, damages and expenses (including, without limitation, reasonable attorneys’ fees, charges and disbursements) incurred by the Purchasers as a result of claims brought by third parties arising out of or relating to any inaccuracy in or breach of the representations, warranties or covenants made by the Company herein.

7.2 Indemnification Procedure . Any party entitled to indemnification under this Article 7 (an “ indemnified party ”) will give written notice to the indemnifying party of any matter giving rise to a claim for indemnification; provided, that the failure of any party entitled to indemnification hereunder to give notice as provided herein shall not relieve the indemnifying party of its obligations under this Article 7 except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In case any such action, proceeding or claim is brought against an indemnified party in respect of which indemnification is sought hereunder, the indemnifying party shall be entitled to participate in and, unless in the reasonable judgment of the indemnifying party a conflict of interest between it and the indemnified party exists with respect to such action, proceeding or claim (in which case the indemnifying party shall be responsible for the reasonable fees and expenses of one separate counsel for the indemnified parties), to assume the defense thereof with counsel reasonably satisfactory to the indemnified party. In the event that the indemnifying party advises an indemnified party that it will contest such a claim for indemnification hereunder, or fails, within 30 days of receipt of any indemnification notice (the “ Defense Period ”) to notify, in writing, such person of its election to defend, settle or compromise, at its sole cost and expense, any action, proceeding or claim (or discontinues its defense at any time after it commences such defense), then the indemnified party may, at its option, defend, settle or otherwise compromise or pay such action or claim. In any event, unless and until the indemnifying party elects in writing to assume and does so assume the defense of any such claim, proceeding or action, the indemnified party’s costs and expenses arising out of the defense, settlement or compromise of any such action, claim or proceeding, only to the extent incurred after the expiration of the Defense Period, shall be losses subject to indemnification hereunder. The indemnified party shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the indemnified party which relates to such action or claim. The indemnifying party shall keep the indemnified party fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. If the indemnifying party elects to defend any such action or claim, then the indemnified party shall be entitled to participate in such defense with counsel of its choice at its sole cost and expense. The indemnifying party shall not be liable for any settlement of any action, claim or proceeding effected without its prior written consent. Notwithstanding anything in this Article 7 to the contrary, the indemnifying party shall not, without the indemnified party’s prior written consent, settle or compromise any claim or consent to entry of any judgment in respect thereof which imposes any future obligation on the indemnified party or which does not include, as an unconditional term thereof, the giving by the claimant or the plaintiff to the indemnified party of a release from all liability in respect of such claim. The indemnification obligations to defend the indemnified party required by this Article 7 shall be made by periodic payments of the amount thereof during the course of investigation or defense, as and when bills are received or expense, loss, damage or liability is incurred, so long as the indemnified party shall refund such moneys if it is ultimately determined by a court of competent jurisdiction that such party was not entitled to indemnification. The indemnity agreements contained herein shall be in addition to (a) any cause of action or similar rights of the indemnified party against the indemnifying party or others, and (b) any liabilities the indemnifying party may be subject to pursuant to the law.

7.3 Exclusivity of Remedy . With the exception of the indemnification provisions set forth above in Section 7.1 and the right of redemption set forth in Article VII.A.(v) of the Certificate of Designations, the Purchasers shall not have the right to recover for any damages or claims arising out of or relating to any inaccuracy in or breach of the representations or warranties made by the Company herein.

ARTICLE 8

MISCELLANEOUS

8.1 Fees and Expenses . Each party shall pay the fees and expenses of its advisors, counsel, accountants and other experts, if any, and all other expenses, incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement and the transactions contemplated hereby; provided, however, that the Company shall pay all fees and expenses, including without limitation attorneys’ fees and expenses (including disbursements and out-of-pocket expenses), incurred by the Purchasers in connection with the preparation, negotiation, execution and delivery of the Transaction Documents and the transactions contemplated thereunder, which payment shall be made at the Closing (which payments shall not exceed in the aggregate $50,000 and may be withheld from the amounts delivered to the Company by the Purchasers at the Closing).

8.2 Specific Performance; Consent to Jurisdiction; Venue .

(a)  The Company and the Purchasers acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement or the other Transaction Documents were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement or the other Transaction Documents and to enforce specifically the terms and provisions hereof or thereof without the requirement of posting a bond or providing any other security, this being in addition to any other remedy to which any of them may be entitled by law or equity.

(b)  The parties agree that venue for any dispute arising under this Agreement will lie exclusively in the state or federal courts located in New York County, New York, and the parties irrevocably waive any right to raise forum non conveniens or any other argument that New York is not the proper venue. The parties irrevocably consent to personal jurisdiction in the state and federal courts of the state of New York. The Company and each Purchaser consent to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 8.2 shall affect or limit any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. In addition, the prevailing party in any dispute arising under this Agreement shall be entitled to recover its fees and expenses, including, without limitation, all reasonable attorneys’ fees and expenses.

8.3 Entire Agreement; Amendment . This Agreement and the Transaction Documents contain the entire understanding and agreement of the parties with respect to the matters covered hereby and, except as specifically set forth herein or in the other Transaction Documents, neither the Company nor any Purchaser make any representation, warranty, covenant or undertaking with respect to such matters, and they supersede all prior understandings and agreements with respect to said subject matter, all of which are merged herein. No provision of this Agreement may be waived or amended on behalf of all Purchasers other than by a written instrument signed by the Company and the Requisite Holders. In addition to the foregoing, no provision of this Agreement may be amended to increase the financial obligations of any Purchaser under this Agreement other than by a written instrument signed by such Purchaser. Nothing provided in this Section 8.3 shall limit an individual Purchaser’s right to waive or amend any provision of this Agreement on its own behalf. The Purchasers acknowledge that any waiver effected in accordance with this Section 8.3 shall be binding upon each Purchaser (and their permitted assigns) and the Company, including, without limitation, a waiver that has an adverse effect on any or all Purchasers.

8.4 Notices . Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall be effective (a) upon hand delivery or by telecopy, electronic mail or facsimile at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

If to the Company or its Subsidiaries:

La Jolla Pharmaceutical Company
4365 Executive Drive, Suite 300
San Diego, CA 92121
Attention: Deirdre Gillespie
Telephone No.: (858) 452-6600
Telecopy No.: (858) 626-2851
Email address: deirdre.gillespie@ljpc.com

with copies to:

Goodwin Procter LLP
4365 Executive Drive, Suite 300
San Diego, CA 92121
Attention: Ryan Murr
Telephone No.: (858) 202-2727
Telecopy No.: (858) 546-4464
Email address: rmurr@goodwinprocter.com

If to any Purchaser:

At the address of such Purchaser set forth on the signature page to this Agreement, with copies to Purchaser’s counsel, if any, as set forth on the signature page or as specified in writing by such Purchaser.

With a copy to:

Cooley LLP
4401 Eastgate Mall
San Diego, CA 92121
Attention: Ethan Christensen
Telephone No.: (858) 550-6076
Telecopy No.: (858) 550-6420
Email address: echristensen@cooley.com

Any party hereto may from time to time change its address for notices by giving written notice of such changed address to the other party hereto.

8.5 Waivers . No waiver by either party of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it thereafter.

8.6 Headings . The article, section and subsection headings in this Agreement are for convenience only and shall not constitute a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof.

8.7 Successors and Assigns . This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. Subject to the limitations set forth in Article 4 of this Agreement, the Purchasers may assign the Securities and its rights under this Agreement and the other Transaction Documents and any other rights hereto and thereto without the consent of the Company.

8.8 No Third Party Beneficiaries . This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

8.9 Governing Law . This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to any of the conflicts of law principles which would result in the application of the substantive law of another jurisdiction. This Agreement shall not be interpreted or construed with any presumption against the party causing this Agreement to be drafted.

8.10 Survival . The representations and warranties of the Company and the Purchasers shall terminate upon the Closing Date; provided, however, that such termination shall have no affect on the rights of the Purchasers under Section 7 or Article VII of the Certificate of Designations. The agreements and covenants set forth in Articles 1, 3, 4, 6, 7 and 8 of this Agreement shall survive the Closing hereunder indefinitely.

8.11 Counterparts . This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and shall become effective when counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties need not sign the same counterpart.

8.12 Publicity . The Company agrees that it will not disclose, and will not include in any public announcement, the names of the Purchasers without the consent of the Purchasers, or unless and until such disclosure is required by law, rule or applicable regulation, and then only to the extent of such requirement. Notwithstanding the foregoing, the Purchasers consent to being identified in any filings the Company makes with the SEC to the extent required by law or the rules and regulations of the SEC.

8.13 Severability . The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction shall determine that any one or more of the provisions or part of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement and this Agreement shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to the maximum extent possible.

8.14 Further Assurances . From and after the date of this Agreement, upon the request of the Purchasers or the Company, the Company and each Purchaser shall execute and deliver such instruments, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement and the other Transaction Documents

8.15 Representation of Lead Purchaser . It is acknowledged by each Purchaser that the purchaser listed as the Lead Purchaser on Exhibit A hereto (the “ Lead Purchaser ”) has retained Cooley LLP to act as its counsel in connection with the transactions contemplated by the Transaction Documents and that Cooley LLP has not acted as counsel for any Purchaser, other than the Lead Purchaser, in connection with the transactions contemplated by the Transaction Documents and that none of such Purchasers has the status of a client for conflict of interest or any other purposes as a result thereof.

8.16 Independent Nature of Purchasers’ Obligations and Rights . The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchaser as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.

8.17 Force Majeure . Notwithstanding any provision herein to the contrary, the failure of any party to timely satisfy obligations hereunder shall be excused to the extent that (i) such failure follows the occurrence of a Force Majeure Event (defined below), and (ii) such Force Majeure Event has materially adversely affected the ability of such party (or its agents, including banks, transfer agents, and clearinghouses) to perform hereunder. A failure to perform shall be excused only for so long as the Force Majeure Event continues to materially adversely affect such person’s ability to perform. For purposes of this Section, “ Force Majeure Event ” shall mean the occurrence of any of the following events: (a) trading in securities generally on either the Nasdaq Stock Market or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the SEC or FINRA; (b) a general banking moratorium shall have been declared by any of federal, New York or California authorities; (c) an act of war, terrorism or hostility shall have occurred, or (d) a strike, fire, flood, earthquake, accident or other calamity or Act of God shall have occurred.

8.18 Approval of Equity Awards . Within 2 Trading Days following the Closing Date, the Company shall grant the equity compensation awards set forth on Schedule 8.18 attached hereto. Upon execution of this Agreement, each Purchaser shall be deemed to be consenting, as of the Closing Date, to the granting of such awards for purposes of Article XII under the Certificate of Designations.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

1

IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized officers as of the date first above written.

LA JOLLA PHARMACEUTICAL COMPANY

By: /s/ Deirdre Gillespie
Name: Deirdre Gillespie
Title: President and Chief Executive Officer

[SIGNATURE PAGES CONTINUE]

[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: Tang Capital Partners, LP

Signature of Authorized Signatory of Purchaser: /s/ Kevin Tang

Name of Authorized Signatory: Kevin C. Tang
Title of Authorized Signatory: Managing Director

Email Address of Purchaser: kevin@tangcapital.com

Fax Number of Purchaser: (858) 200-3837

Address for Notice of Purchaser:

4401 Eastgate Mall

San Diego, California 92121

Address for Delivery of Securities for Purchaser (if not same as address for notice):

SAME

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

[SIGNATURE PAGES CONTINUE]

2

[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: The Haeyoung and Kevin Tang Foundation, Inc.

Signature of Authorized Signatory of Purchaser: /s/ Kevin Tang

Name of Authorized Signatory: Kevin C. Tang
Title of Authorized Signatory: President

Email Address of Purchaser: kevin@tangcapital.com

Fax Number of Purchaser: (858) 200-3837

Address for Notice of Purchaser:

4401 Eastgate Mall

San Diego, California 92121

Address for Delivery of Securities for Purchaser (if not same as address for notice):

SAME

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

[SIGNATURE PAGES CONTINUE]

3

[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: Boxer Capital, LLC

Signature of Authorized Signatory of Purchaser: /s/ Chris Fuglesang

Name of Authorized Signatory: Chris Fuglesang

Title of Authorized Signatory: Member

Email Address of Purchaser: cfuglesang@tavistock.com

Fax Number of Purchaser: (858) 400-3101

Address for Notice of Purchaser:

445 Marine View Ave., Suite 100

Del Mar, California 92014

Address for Delivery of Securities for Purchaser (if not same as address for notice):

SAME

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

[SIGNATURE PAGES CONTINUE]

4

[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: MVA Investors, LLC

Signature of Authorized Signatory of Purchaser: /s/ Chris Fuglesang

Name of Authorized Signatory: Chris Fuglesang
Title of Authorized Signatory: President

Email Address of Purchaser: cfuglesang@tavistock.com

Fax Number of Purchaser: (858) 400-3101

Address for Notice of Purchaser:

445 Marine View Ave., Suite 100

Del Mar, California 92014

Address for Delivery of Securities for Purchaser (if not same as address for notice):

SAME

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

[SIGNATURE PAGES CONTINUE]

5

[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: RTW Investments, LLC

Signature of Authorized Signatory of Purchaser: /s/ Roderick Wong

Name of Authorized Signatory: Roderick Wong

Title of Authorized Signatory: Managing Member

Email Address of Purchaser: rwong@rtwfunds.com

Fax Number of Purchaser: (646) 597-6998

Address for Notice of Purchaser:

1350 Avenue of the Americas, 28 ^th Floor

New York, New York 10019

Address for Delivery of Securities for Purchaser (if not same as address for notice):

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

[SIGNATURE PAGES CONTINUE]

6

[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: Deirdre Y. Gillespie

Signature of Authorized Signatory of Purchaser: /s/ Deirdre Gillespie

Name of Authorized Signatory: Deirdre Y. Gillespie
Title of Authorized Signatory: President and Chief Executive Officer of La Jolla Pharmaceutical Company

Email Address of Purchaser: deirdre.gillespie@ljpc.com

Fax Number of Purchaser: (858) 626-2851

Address for Notice of Purchaser:

c/o La Jolla Pharmaceutical Company

4365 Executive Drive, Suite 300

San Diego, California 92121

Address for Delivery of Securities for Purchaser (if not same as address for notice):

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

[SIGNATURE PAGES CONTINUE]

7

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: Gail A. Sloan

Signature of Authorized Signatory of Purchaser: /s/ Gail A. Sloan

Name of Authorized Signatory: Gail A. Sloan
Title of Authorized Signatory: Vice President, Finance of La Jolla Pharmaceutical Company

Email Address of Purchaser: gail.sloan@ljpc.com

Fax Number of Purchaser: (858) 626-2851

Address for Notice of Purchaser:

c/o La Jolla Pharmaceutical Company

4365 Executive Drive, Suite 300

San Diego, California 92121

Address for Delivery of Securities for Purchaser (if not same as address for notice):

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

[SIGNATURE PAGES CONTINUE]

8

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: Daniel J. Bryson

Signature of Authorized Signatory of Purchaser: /s/ Daniel J. Bryson

Name of Authorized Signatory: Daniel J. Bryson

Title of Authorized Signatory: Controller of La Jolla Pharmaceutical Company

Email Address of Purchaser: dan.bryson@ljpc.com

Fax Number of Purchaser: (858) 626-2851

Address for Notice of Purchaser:

c/o La Jolla Pharmaceutical Company

4365 Executive Drive, Suite 300

San Diego, California 92121

Address for Delivery of Securities for Purchaser (if not same as address for notice):

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

SCHEDULE I
SCHEDULE OF EXCEPTIONS

EXHIBIT A
LIST OF PURCHASERS
EXHIBIT B
FORM OF CASHLESS WARRANT

9

EXHIBIT C
FORM OF CASH WARRANT

10

EXHIBIT D
FORM OF OFFICER’S CERTIFICATE

11

EXHIBIT E
CERTIFICATE OF DESIGNATIONS

12

EXHIBIT F
INITIAL NET CASH SCHEDULE

13

EXHIBIT G
SIDE LETTER

14

EXHIBIT H
OPINION OF COUNSEL TO COMPANY

15

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

FORM OF SERIES C-2 PREFERRED STOCK PURCHASE WARRANT
LA JOLLA PHARMACEUTICAL COMPANY

Warrant Shares: [        ] Issue Date: [        ], 2010

THIS SERIES C-2 PREFERRED STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, [        ] (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to the close of business on the three year anniversary of the Issue Date (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from La Jolla Pharmaceutical Company, a Delaware corporation (the “ Company ”), up to [        ] shares (the “ Warrant Shares ”) of the Company’s Series C-2 Preferred Stock (the “ Series C-2 Preferred Stock ”) and one or more warrants to purchase shares of the Series D-2 Preferred Stock of the Company (the “ Series D-2 Preferred Stock ”), substantially in the form attached hereto as Exhibit A (each a “ Series D-2 Warrant ” and, collectively with the Warrant Shares, the “ Warrant Securities ”) to purchase up to [        ] shares of the Series D-2 Preferred Stock. The purchase price of one unit (the “ Unit ”) consisting of (i) one Warrant Share and (ii) the corresponding Series D-2 Warrant to purchase one share of Series D-2 Preferred Stock shall be equal to the Exercise Price, as defined in Section 1(b). This Warrant is one of a series of warrants of like tenor issuable by the Company under that certain Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated as of [        ], 2010 (the “ Purchase Agreement ”) and referred to therein as the Cash Warrants. As used herein, “ Warrants ” means all such Cash Warrants.

Section 1. Exercise .

(a)  Exercise of Warrant . Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company (the date of such delivery, the “ Exercise Date ”) of both: (i) a duly executed electronic mail copy of the Notice of Exercise annexed hereto (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company), and (ii) sufficient funds representing the Exercise Price, delivered by wire transfer. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Securities available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days (as defined in the Certificate of Designations, Preferences and Rights of Series C-1 Convertible Preferred Stock, Series C-2 Convertible Preferred Stock, Series D-1 Convertible Preferred Stock and Series D-2 Convertible Preferred Stock of the Company (the “ Certificate of Designations ”)) of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Securities available hereunder shall have the effect of lowering the outstanding number of Warrant Securities purchasable hereunder in an amount equal to the applicable number of Warrant Securities purchased. The Holder and the Company shall maintain records showing the number of Warrant Securities purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within two (2) Trading Days of receipt of such notice. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error. The Holder may provide this Warrant, or an affidavit of lost security, to the Company within a reasonable period after the delivery of any Notice of Exercise related to any partial exercise of this Warrant, and the Company, at its expense, will promptly thereafter issue and deliver to the Holder a new Warrant of like tenor, registered in the name of the Holder and exercisable, in the aggregate, for the remaining Warrant Securities available for purchase under this Warrant. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Securities hereunder, the number of Warrant Securities available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

(b)  Exercise Price . The exercise price of the Warrant Securities under this Warrant shall be $1,000.00 per Unit, subject to adjustment hereunder (the “ Exercise Price ”).

(c)  Issuance of Series D-2 Warrants. Upon the exercise of this Warrant in whole or in part, the Company shall issue to the Holder on the date of such exercise a warrant to purchase shares of the Series D-2 Preferred Stock, substantially in the form attached hereto as Exhibit A (the “ Series D-2 Warrant ”). Each Series D-2 Warrant shall be exercisable for the number of shares of Series D-2 Preferred Stock equal to the number of shares of Series C-2 Preferred Stock reflected in the Notice of Exercise delivered by the Holder pursuant to this Warrant for the exercise hereof in connection with which such Series D-2 Warrant is issued.

(d)  Mandatory Exercise . The Holder agrees to exercise the purchase rights represented by this Warrant in whole within three (3) Trading Days following the closing of the first Strategic Transaction (as defined in the Certificate of Designations) that occurs following the Issue Date, and agrees to deliver a Notice of Exercise in connection therewith, which Notice of Exercise shall be irrevocable. The Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company (i) at least three (3) Trading Days prior to the closing of the Strategic Transaction, a notice stating the date on which such Strategic Transaction is expected to close and (ii) within three (3) Trading Days following the closing of the Strategic Transaction, a notice stating the date on which such Strategic Transaction closed.

(e)  Mechanics of Exercise .

(i)  Delivery of Certificates Upon Exercise . Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the Company to the Holder by physical delivery to the address specified by the Holder in the Notice of Exercise within three (3) Trading Days from the receipt by the Company of the Notice of Exercise and payment of the aggregate Exercise Price as set forth above (“ Warrant Share Delivery Date ”). The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 1(e)(vi) prior to the issuance of such shares, have been paid. To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of the Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver the Warrant Shares issuable upon exercise of the Warrant as required pursuant to the terms hereof.

(ii)  Delivery of Series D-2 Warrants Upon Exercise . The Series D-2 Warrant shall be transmitted by the Company to the Holder by physical delivery to the address specified by the Holder in the Notice of Exercise within three (3) Trading Days from the receipt by the Company of the Notice of Exercise and payment of the aggregate Exercise Price as set forth above (“ Series D-2 Warrant Delivery Date ” and, together with the Warrant Share Delivery Date, the “ Delivery Date ”). The Series D-2 Warrant shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such Series D-2 Warrant for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 1(e)(vi) prior to the issuance of such shares or Series D-2 Warrant, have been paid. To the extent permitted by law, the Company’s obligations to issue and deliver Series D-2 Warrants in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of the Series D-2 Warrants. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver the Series D-2 Warrants issuable upon exercise of the Warrant as required pursuant to the terms hereof.

(iii)  Delivery of New Warrants Upon Exercise . If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

(iv)  Rescission Rights . If the Company fails to cause its transfer agent to transmit to the Holder a certificate or certificates representing the Warrant Shares or the Series D-2 Warrant pursuant to this Section 1(e) by the third (3 ^rd ) Trading Day immediately following the Delivery Date and the payment of the Exercise Price, then the Holder will have the right to rescind such exercise at any time until delivery of such securities.

(v)  No Fractional Shares or Scrip . No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

(vi)  Charges, Taxes and Expenses . Issuance of certificates for Warrant Shares and the Series D-2 Warrant shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate and Series D-2 Warrant, all of which taxes and expenses shall be paid by the Company, and such certificates and Series D-2 Warrants shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares or Series D-2 Warrants are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

(f)  Closing of Books . The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

Section 2. Certain Adjustments .

(a)  Stock Dividends and Splits . If the Company, at any time while this Warrant is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions on shares of Series C-2 Preferred Stock payable in shares of Series C-2 Preferred Stock, (B) subdivides outstanding shares of Series C-2 Preferred Stock into a larger number of shares, or (C) combines (including by way of reverse stock split) outstanding shares of Series C-2 Preferred Stock into a smaller number of shares, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Series C-2 Preferred Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Series C-2 Preferred Stock (excluding treasury shares, if any) outstanding immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

(b)  Pro Rata Distributions . If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Series C-2 Preferred Stock (and not to Holders of the Warrants) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security other than the Series C-2 Preferred Stock, then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the Fair Market Value (as defined below) of one Warrant Share determined as of the record date mentioned above, and of which the numerator shall be such Fair Market Value of one Warrant Share on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Series C-2 Preferred Stock (determined by dividing the amount distributed by the then issued and outstanding shares of Series C-2 Preferred Stock) as determined by the Board of Directors of the Company in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Series C-2 Preferred Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above. The “ Fair Market Value ” shall be determined by the Board of Directors of the Company in good faith.

(c)  Corporate Change . If, at any time while this Warrant is outstanding, the Company effects any Corporate Change (as defined in the Certificate of Designations), then the Warrant shall terminate immediately prior to the closing or other consummation of the event causing the Corporate Change, provided that the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Corporate Change, the securities, cash or property (the “ Alternate Consideration ”) receivable as a result of such merger, consolidation or disposition of assets by a holder of the number of shares of Series C-2 Preferred Stock for which this Warrant is exercisable immediately prior to such event. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Series C-2 Preferred Stock in such Corporate Change, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Series C-2 Preferred Stock are given any choice as to the securities, cash or property to be received in a Corporate Change, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant in connection with such Corporate Change. The terms of any agreement pursuant to which a Corporate Change is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 2(c).

(d)  Notice to Holder .

(i)  Adjustment to Exercise Price . Whenever the Exercise Price or Warrant Shares are adjusted pursuant to any provision of this Section 2, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price and Warrant Shares after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

(ii)  Notice to Allow Exercise by Holder . If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock of the Company (“ Common Stock ”) or the Series C-2 Preferred Stock; (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock or the Series C-2 Preferred Stock; (C) the Company shall authorize the granting to all holders of the Common Stock or the Series C-2 Preferred Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights; (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock or the Series C-2 Preferred Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock or the Series C-2 Preferred Stock is converted into other securities, cash or property; (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock or the Series C-2 Preferred Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock or the Series C-2 Preferred Stock of record shall be entitled to exchange their shares of the Common Stock or the Series C-2 Preferred Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law, the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this Section 2(i) is not intended to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.

Section 3. Transfer of Warrant .

(a)  Transferability . Subject to compliance with any applicable securities laws, the conditions set forth in Section 3(d) hereof and the conditions set forth in the Purchase Agreement, this Warrant and all rights hereunder are transferable, in whole (not in part), upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Securities without having a new Warrant issued.

(b)  New Warrants . This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Securities issuable pursuant thereto.

(c)  Warrant Register . The Company shall register this Warrant, upon records to be maintained by the Company for that purpose, in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

(d)  Transfer Restrictions . If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “ Securities Act ”) and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of counsel satisfactory to the Company (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii) that the transferor or transferee execute and deliver to the Company an investment letter in form and substance acceptable to the Company and (iii) that the transferee be an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a qualified institutional buyer as defined in Rule 144A(a)(1) promulgated under the Securities Act.

Section 4. Investment Intent; Limited Transferability .

(a)  By accepting this Warrant, the Holder represents to the Company that it understands that this Warrant has not been, and any securities obtainable upon exercise of this Warrant may not have not been registered for sale under the Securities Act or any state securities or “blue sky” laws and are being offered and sold to the Holder pursuant to one or more exemptions from the registration requirements of the Securities Act and applicable State securities or “blue sky” laws. In the absence of an effective registration of such securities or an exemption therefrom, any certificates for such securities shall bear a legend substantially similar to the legend set forth in the Purchase Agreement. The Holder understands that it may have to bear the economic risk of its investment in this Warrant and any securities obtainable upon exercise of this Warrant for an indefinite period of time, until such securities have been registered under the Securities Act and any applicable state securities or “blue sky” laws and therefore cannot be sold unless subsequently registered under such laws, or an exemption from such registration is available. The Holder further represents to the Company, by accepting this Warrant, that it has full power and authority to accept this Warrant and make the representations set forth herein.

(b)  The Holder agrees and acknowledges that this Warrant may not be sold, transferred, assigned or hypothecated by the Holder except in compliance with the provisions of the Securities Act and any applicable State securities or “blue sky” laws.

Section 5. Miscellaneous .

(a)  No Rights as Stockholder Until Exercise . This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to the exercise hereof. Upon the surrender of this Warrant and the payment of the aggregate Exercise Price, the Warrant Securities so purchased shall be and be deemed to be issued to such Holder as the record owner of such shares as of the close of business on the later of the date of such surrender and payment.

(b)  Loss, Theft, Destruction or Mutilation of Warrant . The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

(c)  Saturdays, Sundays, Holidays, etc . If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.

(d)  Authorized Shares .

The Company covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that all Warrant Securities shall be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market (as defined in the Certificate of Designations). The Company covenants that all Warrant Securities that are required to be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

The Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

(e)  Jurisdiction . All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

(f)  Restrictions . The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

(g)  Nonwaiver and Expenses . No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

(h)  Notices . Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

(i)  Limitation of Liability . No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Series C-2 Preferred Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

(j)  Remedies . Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

(k)  Successors and Assigns . Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by any such Holder or holder of Warrant Shares.

(l)  Amendment; Waiver . No provision of this Warrant may be waived or amended on behalf of all holders of Warrants other than by a written instrument signed by the Company and the holders holding at least 66-2/3% of the sum of (i) the shares of Series C-2 Preferred Stock of the Company that may be acquired upon exercise in full of all then outstanding Warrants and (ii) the shares of Series D-2 Preferred Stock of the Company that may be acquired upon exercise in full for cash of the Series D-2 Warrants that may be acquired upon exercise in full of all then outstanding Warrants, voting together as a single class. In addition to the foregoing, no provision of this Warrant may be amended to increase the financial obligations of Holder under this Warrant other than by a written instrument signed by Holder. Nothing provided in this Section 5(l) shall limit an individual holder’s right to waive or amend any provision of any Warrant on its own behalf. The Holder acknowledges that any amendment or waiver effected in accordance with this Section 5(l) shall be binding upon the Holder (and its permitted assigns) and the Company, including, without limitation, an amendment or waiver that is not agreed to by the Holder or that has an adverse effect on any or all holders of Warrants.

(m)  Severability . Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

(n)  Headings . The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

(o)  Force Majeure . Notwithstanding any provision herein to the contrary, the failure of any party to timely satisfy obligations hereunder shall be excused to the extent that (i) such failure follows the occurrence of a Force Majeure Event (defined below), and (ii) such Force Majeure Event has materially adversely affected the ability of such party (or its agents, including banks, transfer agents, and clearinghouses) to perform hereunder. A failure to perform shall be excused only for so long as the Force Majeure Event continues to materially adversely affect such person’s ability to perform. For purposes of this Section, “ Force Majeure Event ” shall mean the occurrence of any of the following events: (a) trading in securities generally on either the Nasdaq Stock Market or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the SEC or FINRA; (b) a general banking moratorium shall have been declared by any of federal, New York or California authorities; (c) an act of war, terrorism or hostility shall have occurred, or (d) a strike, fire, flood, earthquake, accident or other calamity or Act of God shall have occurred.

** ** ** ** **

1

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

LA JOLLA PHARMACEUTICAL COMPANY

By:
Name: Deirdre Gillespie
Title: President and Chief Executive Officer

AGREED AND ACCEPTED:

[        ]

By:
Name:
Title:

NOTICE OF EXERCISE

TO: [        ]

1.  The undersigned hereby elects to purchase        Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

2.  Payment shall be made in lawful money of the United States.

3.  Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered by physical delivery of a certificate to:

4.  Accredited Investor . The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

2

ASSIGNMENT FORM
(To assign the foregoing warrant, execute
this form and supply required information.
Do not use this form to exercise the warrant.)

FOR VALUE RECEIVED, all [        ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

       whose address is

       .

Dated:        ,       

Holder’s Signature:

Holder’s Address:

Signature Guaranteed:       

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

3

EXHIBIT A
Form of Series D-2 Preferred Stock Purchase Warrant

4

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

FORM OF SERIES D-1 PREFERRED STOCK PURCHASE WARRANT
LA JOLLA PHARMACEUTICAL COMPANY

Warrant Shares: [        ] Issue Date: [        ]

THIS SERIES D-1 PREFERRED STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, [        ] (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to the close of business on the three year anniversary of the Issue Date (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from La Jolla Pharmaceutical Company, a Delaware corporation (the “ Company ”), up to [        ] shares (the “ Warrant Shares ”) of the Company’s Series D-1 Preferred Stock (the “ Series D-1 Preferred Stock ”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b). This Warrant is one of a series of warrants of like tenor issuable by the Company under that certain Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated as of [        ], 2010 (the “ Purchase Agreement ”) and referred to therein as the Cashless Warrants. As used herein, “ Warrants ” means all such Cashless Warrants.

Section 1. Exercise .

(a)  Exercise of Warrant . Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company (the date of such delivery, the “ Exercise Date ”) of both: (i) a duly executed electronic mail copy of the Notice of Exercise annexed hereto (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company), and (ii) if applicable, sufficient funds representing the Exercise Price, delivered by wire transfer. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days (as defined in the Certificate of Designations, Preferences and Rights of Series C-1 Convertible Preferred Stock, Series C-2 Convertible Preferred Stock, Series D-1 Convertible Preferred Stock and Series D-2 Convertible Preferred Stock of the Company (the “ Certificate of Designations ”)) of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within two (2) Trading Days of receipt of such notice. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error. The Holder may provide this Warrant, or an affidavit of lost security, to the Company within a reasonable period after the delivery of any Notice of Exercise related to any partial exercise of this Warrant, and the Company, at its expense, will promptly thereafter issue and deliver to the Holder a new Warrant of like tenor, registered in the name of the Holder and exercisable, in the aggregate, for the remaining Warrant Shares available for purchase under this Warrant. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

(b)  Exercise Price . The exercise price of the Warrant Shares under this Warrant shall be $1,000.00 per share, subject to adjustment hereunder (the “ Exercise Price ”).

(c)  Cashless Exercise . If at any time prior to the Termination Date the Holder elects to exercise this Warrant and on the Trading Day prior to the Exercise Date the Closing Sales Price (as defined in the Certificate of Designations) is greater than the then applicable Conversion Price (as defined in the Certificate of Designations) of the Series D-1 Preferred Stock, the Holder of this Warrant may elect to exercise this Warrant in whole or in part by means of a “cashless exercise.” In the event of a “cashless exercise,” by delivery to the Company of a duly completed and executed Notice of Exercise in the form attached hereto, the Holder shall be entitled to receive, without payment of any consideration, the number of Warrant Shares, rounded to the nearest 1/1000 ^th of a Warrant Share, equal to the difference between (A) the aggregate face amount of the number of Warrant Shares as to which the Warrant is then being exercised minus (B) the quotient of (1) the product of (x) the face amount of the Warrant being exercised and (y) the then Conversion Price, divided by (2) the Closing Sales Price on the Trading Day prior to the Exercise Date.

(d)  Mechanics of Exercise .

(i)  Delivery of Certificates Upon Exercise . Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the Company to the Holder by physical delivery to the address specified by the Holder in the Notice of Exercise within three (3) Trading Days from the receipt by the Company of the Notice of Exercise, and if applicable, payment of the aggregate Exercise Price as set forth above (“ Warrant Share Delivery Date ”). The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 1(d)(iv) prior to the issuance of such shares, have been paid. To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of the Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver the Warrant Shares issuable upon exercise of the Warrant as required pursuant to the terms hereof.

(ii)  Delivery of New Warrants Upon Exercise . If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

(iii)  Rescission Rights . If the Company fails to cause its transfer agent to transmit to the Holder a certificate or certificates representing the Warrant Shares pursuant to this Section 1(d)(iii) by the third (3 ^rd ) Trading Day immediately following the Warrant Share Delivery Date and the payment of the Exercise Price, then the Holder will have the right to rescind such exercise at any time until delivery of such securities.

(iv)  Charges, Taxes and Expenses . Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

(e)  Closing of Books . The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

Section 2. Certain Adjustments .

(a)  Stock Dividends and Splits . If the Company, at any time while this Warrant is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions on shares of Series D-1 Preferred Stock payable in shares of Series D-1 Preferred Stock, (B) subdivides outstanding shares of Series D-1 Preferred Stock into a larger number of shares, or (C) combines (including by way of reverse stock split) outstanding shares of Series D-1 Preferred Stock into a smaller number of shares, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Series D-1 Preferred Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Series D-1 Preferred Stock (excluding treasury shares, if any) outstanding immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

(b)  Pro Rata Distributions . If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Series D-1 Preferred Stock (and not to Holders of the Warrants) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security other than the Series D-1 Preferred Stock, then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the Fair Market Value (as defined below) of one Warrant Share determined as of the record date mentioned above, and of which the numerator shall be such Fair Market Value of one Warrant Share on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Series D-1 Preferred Stock (determined by dividing the amount distributed by the then issued and outstanding shares of Series D-1 Preferred Stock) as determined by the Board of Directors of the Company in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Series D-1 Preferred Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above. The “ Fair Market Value ” shall be determined by the Board of Directors of the Company in good faith.

(c)  Corporate Change . If, at any time while this Warrant is outstanding, the Company effects any Corporate Change (as defined in the Certificate of Designations), then the Warrant shall terminate immediately prior to the closing or other consummation of the event causing the Corporate Change, provided that the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Corporate Change, the securities, cash or property (the “ Alternate Consideration ”) receivable as a result of such merger, consolidation or disposition of assets by a holder of the number of shares of Series D-1 Preferred Stock for which this Warrant is exercisable immediately prior to such event. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Series D-1 Preferred Stock in such Corporate Change, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Series D-1 Preferred Stock are given any choice as to the securities, cash or property to be received in a Corporate Change, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant in connection with such Corporate Change. The terms of any agreement pursuant to which a Corporate Change is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 2(c).

(d)  Notice to Holder .

(i)  Adjustment to Exercise Price . Whenever the Exercise Price or Warrant Shares are adjusted pursuant to any provision of this Section 2, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price and Warrant Shares after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

(ii)  Notice to Allow Exercise by Holder . If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock of the Company (the “ Common Stock ”) or the Series D-1 Preferred Stock; (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock or the Series D-1 Preferred Stock; (C) the Company shall authorize the granting to all holders of the Common Stock or the Series D-1 Preferred Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights; (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock or the Series D-1 Preferred Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock or the Series D-1 Preferred Stock is converted into other securities, cash or property; (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock or the Series D-1 Preferred Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock or the Series D-1 Preferred Stock of record shall be entitled to exchange their shares of the Common Stock or the Series D-1 Preferred Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law, the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this Section 2(i) is not intended to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.

Section 3. Transfer of Warrant .

(a)  Transferability . Subject to compliance with any applicable securities laws, the conditions set forth in Section 3(d) hereof and the conditions set forth in the Purchase Agreement, this Warrant and all rights hereunder are transferable, in whole (not in part), upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

(b)  New Warrants . This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

(c)  Warrant Register . The Company shall register this Warrant, upon records to be maintained by the Company for that purpose, in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

(d)  Transfer Restrictions . If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “ Securities Act ”) and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of counsel satisfactory to the Company (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii) that the transferor or transferee execute and deliver to the Company an investment letter in form and substance acceptable to the Company and (iii) that the transferee be an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a qualified institutional buyer as defined in Rule 144A(a)(1) promulgated under the Securities Act.

Section 4. Investment Intent; Limited Transferability .

(a)  By accepting this Warrant, the Holder represents to the Company that it understands that this Warrant has not been, and any securities obtainable upon exercise of this Warrant may not have not been registered for sale under the Securities Act or any state securities or “blue sky” laws and are being offered and sold to the Holder pursuant to one or more exemptions from the registration requirements of the Securities Act and applicable State securities or “blue sky” laws. In the absence of an effective registration of such securities or an exemption therefrom, any certificates for such securities shall bear a legend substantially similar to the legend set forth in the Purchase Agreement. The Holder understands that it may have to bear the economic risk of its investment in this Warrant and any securities obtainable upon exercise of this Warrant for an indefinite period of time, until such securities have been registered under the Securities Act and any applicable state securities or “blue sky” laws and therefore cannot be sold unless subsequently registered under such laws, or an exemption from such registration is available. The Holder further represents to the Company, by accepting this Warrant, that it has full power and authority to accept this Warrant and make the representations set forth herein.

(b)  The Holder agrees and acknowledges that this Warrant may not be sold, transferred, assigned or hypothecated by the Holder except in compliance with the provisions of the Securities Act and any applicable State securities or “blue sky” laws.

Section 5. Miscellaneous .

(a)  No Rights as Stockholder Until Exercise . This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to the exercise hereof. Upon the surrender of this Warrant and the payment of the aggregate Exercise Price, the Warrant Shares so purchased shall be and be deemed to be issued to such Holder as the record owner of such shares as of the close of business on the later of the date of such surrender and payment.

(b)  Loss, Theft, Destruction or Mutilation of Warrant . The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

(c)  Saturdays, Sundays, Holidays, etc . If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.

(d)  Authorized Shares .

The Company covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that all Warrant Shares shall be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market (as defined in the Certificate of Designations). The Company covenants that all Warrant Shares that are required to be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

The Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

(e)  Jurisdiction . All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

(f)  Restrictions . The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

(g)  Nonwaiver and Expenses . No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

(h)  Notices . Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

(i)  Limitation of Liability . No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Series D-1 Preferred Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

(j)  Remedies . Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

(k)  Successors and Assigns . Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by any such Holder or holder of Warrant Shares.

(l)  Amendment; Waiver . No provision of this Warrant may be waived or amended on behalf of all holders of Warrants other than by a written instrument signed by the Company and the holders holding at least 66-2/3% of the shares of Series D-1 Preferred Stock of the Company that may be acquired upon exercise in full of all then outstanding Warrants. In addition to the foregoing, no provision of this Warrant may be amended to increase the financial obligations of Holder under this Warrant other than by a written instrument signed by Holder. Nothing provided in this Section 5(l) shall limit an individual holder’s right to waive or amend any provision of any Warrant on its own behalf. The Holder acknowledges that any amendment or waiver effected in accordance with this Section 5(l) shall be binding upon the Holder (and its permitted assigns) and the Company, including, without limitation, an amendment or waiver that is not agreed to by the Holder or that has an adverse effect on any or all holders of Warrants.

(m)  Severability . Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

(n)  Headings . The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

(o)  Force Majeure . Notwithstanding any provision herein to the contrary, the failure of any party to timely satisfy obligations hereunder shall be excused to the extent that (i) such failure follows the occurrence of a Force Majeure Event (defined below), and (ii) such Force Majeure Event has materially adversely affected the ability of such party (or its agents, including banks, transfer agents, and clearinghouses) to perform hereunder. A failure to perform shall be excused only for so long as the Force Majeure Event continues to materially adversely affect such person’s ability to perform. For purposes of this Section, “ Force Majeure Event ” shall mean the occurrence of any of the following events: (a) trading in securities generally on either the Nasdaq Stock Market or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the SEC or FINRA; (b) a general banking moratorium shall have been declared by any of federal, New York or California authorities; (c) an act of war, terrorism or hostility shall have occurred, or (d) a strike, fire, flood, earthquake, accident or other calamity or Act of God shall have occurred.

** ** ** ** **

1

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

LA JOLLA PHARMACEUTICAL COMPANY

By:
Name: Deirdre Gillespie
Title: President and Chief Executive Officer

AGREED AND ACCEPTED:

[        ]

By:
Name:
Title:

NOTICE OF EXERCISE

TO: [        ]

1.         The undersigned hereby elects to purchase        Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

       The undersigned hereby elects to purchase        Warrant Shares of the Company pursuant to the terms of the net exercise provisions set forth in Section 1(c) of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any.

2.  Payment shall be made in lawful money of the United States.

3.  Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered by physical delivery of a certificate to:

4.  Accredited Investor . The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

2

ASSIGNMENT FORM
(To assign the foregoing warrant, execute
this form and supply required information.
Do not use this form to exercise the warrant.)

FOR VALUE RECEIVED, all [        ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

       whose address is

       .

Dated:        ,       

Holder’s Signature:

Holder’s Address:

Signature Guaranteed:       

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

3

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

FORM OF SERIES D-2 PREFERRED STOCK PURCHASE WARRANT
LA JOLLA PHARMACEUTICAL COMPANY

Warrant Shares: [        ] Issue Date: [        ]

THIS SERIES D-2 PREFERRED STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, [        ] (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to the close of business on the three year anniversary of the Issue Date (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from La Jolla Pharmaceutical Company, a Delaware corporation (the “ Company ”), up to [        ] shares (the “ Warrant Shares ”) of the Company’s Series D-2 Preferred Stock (the “ Series D-2 Preferred Stock ”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b). This Warrant is one of a series of warrants of like tenor issuable by the Company under that certain Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated as of [        ], 2010 (the “ Purchase Agreement ”) and referred to therein as the Subsequent Cashless Warrants. As used herein, “ Warrants ” means all such Subsequent Cashless Warrants.

Section 1. Exercise .

(a)  Exercise of Warrant . Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company (the date of such delivery, the “ Exercise Date ”) of both: (i) a duly executed electronic mail copy of the Notice of Exercise annexed hereto (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company), and (ii) if applicable, sufficient funds representing the Exercise Price, delivered by wire transfer. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days (as defined in the Certificate of Designations, Preferences and Rights of Series C-1 Convertible Preferred Stock, Series C-2 Convertible Preferred Stock, Series D-1 Convertible Preferred Stock and Series D-2 Convertible Preferred Stock of the Company (the “ Certificate of Designations ”)) of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within two (2) Trading Days of receipt of such notice. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error. The Holder may provide this Warrant, or an affidavit of lost security, to the Company within a reasonable period after the delivery of any Notice of Exercise related to any partial exercise of this Warrant, and the Company, at its expense, will promptly thereafter issue and deliver to the Holder a new Warrant of like tenor, registered in the name of the Holder and exercisable, in the aggregate, for the remaining Warrant Shares available for purchase under this Warrant. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

(b)  Exercise Price . The exercise price of the Warrant Shares under this Warrant shall be $1,000.00 per share, subject to adjustment hereunder (the “ Exercise Price ”).

(c)  Cashless Exercise . If at any time prior to the Termination Date the Holder elects to exercise this Warrant and on the Trading Day prior to the Exercise Date the Closing Sales Price (as defined in the Certificate of Designations) is greater than the then applicable Conversion Price (as defined in the Certificate of Designations) of the Series D-2 Preferred Stock, the Holder of this Warrant may elect to exercise this Warrant in whole or in part by means of a “cashless exercise.” In the event of a “cashless exercise,” by delivery to the Company of a duly completed and executed Notice of Exercise in the form attached hereto, the Holder shall be entitled to receive, without payment of any consideration, the number of Warrant Shares, rounded to the nearest 1/1000 ^th of a Warrant Share, equal to the difference between (A) the aggregate face amount of the number of Warrant Shares as to which the Warrant is then being exercised minus (B) the quotient of (1) the product of (x) the face amount of the Warrant being exercised and (y) the then Conversion Price, divided by (2) the Closing Sales Price on the Trading Day prior to the Exercise Date.

(d)  Mechanics of Exercise .

(i)  Delivery of Certificates Upon Exercise . Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the Company to the Holder by physical delivery to the address specified by the Holder in the Notice of Exercise within three (3) Trading Days from the receipt by the Company of the Notice of Exercise, and if applicable, payment of the aggregate Exercise Price as set forth above (“ Warrant Share Delivery Date ”). The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 1(d)(iv) prior to the issuance of such shares, have been paid. To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of the Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver the Warrant Shares issuable upon exercise of the Warrant as required pursuant to the terms hereof.

(ii)  Delivery of New Warrants Upon Exercise . If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

(iii)  Rescission Rights . If the Company fails to cause its transfer agent to transmit to the Holder a certificate or certificates representing the Warrant Shares pursuant to this Section 1(d)(iii) by the third (3 ^rd ) Trading Day immediately following the Warrant Share Delivery Date and the payment of the Exercise Price, then the Holder will have the right to rescind such exercise at any time until delivery of such securities.

(iv)  Charges, Taxes and Expenses . Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

(e)  Closing of Books . The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

Section 2. Certain Adjustments .

(a)  Stock Dividends and Splits . If the Company, at any time while this Warrant is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions on shares of Series D-2 Preferred Stock payable in shares of Series D-2 Preferred Stock, (B) subdivides outstanding shares of Series D-2 Preferred Stock into a larger number of shares, or (C) combines (including by way of reverse stock split) outstanding shares of Series D-2 Preferred Stock into a smaller number of shares, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Series D-2 Preferred Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Series D-2 Preferred Stock (excluding treasury shares, if any) outstanding immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

(b)  Pro Rata Distributions . If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Series D-2 Preferred Stock (and not to Holders of the Warrants) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security other than the Series D-2 Preferred Stock, then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the Fair Market Value (as defined below) of one Warrant Share determined as of the record date mentioned above, and of which the numerator shall be such Fair Market Value of one Warrant Share on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Series D-2 Preferred Stock (determined by dividing the amount distributed by the then issued and outstanding shares of Series D-2 Preferred Stock) as determined by the Board of Directors of the Company in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Series D-2 Preferred Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above. The “ Fair Market Value ” shall be determined by the Board of Directors of the Company in good faith.

(c)  Corporate Change . If, at any time while this Warrant is outstanding, the Company effects any Corporate Change (as defined in the Certificate of Designations), then the Warrant shall terminate immediately prior to the closing or other consummation of the event causing the Corporate Change, provided that the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Corporate Change, the securities, cash or property (the “ Alternate Consideration ”) receivable as a result of such merger, consolidation or disposition of assets by a holder of the number of shares of Series D-2 Preferred Stock for which this Warrant is exercisable immediately prior to such event. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Series D-2 Preferred Stock in such Corporate Change, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Series D-2 Preferred Stock are given any choice as to the securities, cash or property to be received in a Corporate Change, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant in connection with such Corporate Change. The terms of any agreement pursuant to which a Corporate Change is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 2(c).

(d)  Notice to Holder .

(i)  Adjustment to Exercise Price . Whenever the Exercise Price or Warrant Shares are adjusted pursuant to any provision of this Section 2, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price and Warrant Shares after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

(ii)  Notice to Allow Exercise by Holder . If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock of the Company (“ Common Stock ”) or the Series D-2 Preferred Stock; (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock or the Series D-2 Preferred Stock; (C) the Company shall authorize the granting to all holders of the Common Stock or the Series D-2 Preferred Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights; (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock or the Series D-2 Preferred Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock or the Series D-2 Preferred Stock is converted into other securities, cash or property; (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock or the Series D-2 Preferred Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock or the Series D-2 Preferred Stock of record shall be entitled to exchange their shares of the Common Stock or the Series D-2 Preferred Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law, the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this Section 2(i) is not intended to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.

Section 3. Transfer of Warrant .

(a)  Transferability . Subject to compliance with any applicable securities laws, the conditions set forth in Section 3(d) hereof and the conditions set forth in the Purchase Agreement, this Warrant and all rights hereunder are transferable, in whole (not in part), upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

(b)  New Warrants . This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

(c)  Warrant Register . The Company shall register this Warrant, upon records to be maintained by the Company for that purpose, in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

(d)  Transfer Restrictions . If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “ Securities Act ”) and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of counsel satisfactory to the Company (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii) that the transferor or transferee execute and deliver to the Company an investment letter in form and substance acceptable to the Company and (iii) that the transferee be an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a qualified institutional buyer as defined in Rule 144A(a)(1) promulgated under the Securities Act.

Section 4. Investment Intent; Limited Transferability .

(a)  By accepting this Warrant, the Holder represents to the Company that it understands that this Warrant has not been, and any securities obtainable upon exercise of this Warrant may not have not been registered for sale under the Securities Act or any state securities or “blue sky” laws and are being offered and sold to the Holder pursuant to one or more exemptions from the registration requirements of the Securities Act and applicable State securities or “blue sky” laws. In the absence of an effective registration of such securities or an exemption therefrom, any certificates for such securities shall bear a legend substantially similar to the legend set forth in the Purchase Agreement. The Holder understands that it may have to bear the economic risk of its investment in this Warrant and any securities obtainable upon exercise of this Warrant for an indefinite period of time, until such securities have been registered under the Securities Act and any applicable state securities or “blue sky” laws and therefore cannot be sold unless subsequently registered under such laws, or an exemption from such registration is available. The Holder further represents to the Company, by accepting this Warrant, that it has full power and authority to accept this Warrant and make the representations set forth herein.

(b)  The Holder agrees and acknowledges that this Warrant may not be sold, transferred, assigned or hypothecated by the Holder except in compliance with the provisions of the Securities Act and any applicable State securities or “blue sky” laws.

Section 5. Miscellaneous .

(a)  No Rights as Stockholder Until Exercise . This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to the exercise hereof. Upon the surrender of this Warrant and the payment of the aggregate Exercise Price, the Warrant Shares so purchased shall be and be deemed to be issued to such Holder as the record owner of such shares as of the close of business on the later of the date of such surrender and payment.

(b)  Loss, Theft, Destruction or Mutilation of Warrant . The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

(c)  Saturdays, Sundays, Holidays, etc . If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.

(d)  Authorized Shares .

The Company covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that all Warrant Shares shall be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market (as defined in the Certificate of Designations). The Company covenants that all Warrant Shares that are required to be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

The Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

(e)  Jurisdiction . All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

(f)  Restrictions . The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

(g)  Nonwaiver and Expenses . No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

(h)  Notices . Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

(i)  Limitation of Liability . No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Series D-2 Preferred Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

(j)  Remedies . Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

(k)  Successors and Assigns . Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by any such Holder or holder of Warrant Shares.

(l)  Amendment; Waiver . No provision of this Warrant may be waived or amended on behalf of all holders of Warrants other than by a written instrument signed by the Company and the holders holding at least 66-2/3% of the shares of Series D-2 Preferred Stock of the Company that may be acquired upon exercise in full of all then outstanding Warrants. In addition to the foregoing, no provision of this Warrant may be amended to increase the financial obligations of Holder under this Warrant other than by a written instrument signed by Holder. Nothing provided in this Section 5(l) shall limit an individual holder’s right to waive or amend any provision of any Warrant on its own behalf. The Holder acknowledges that any amendment or waiver effected in accordance with this Section 5(l) shall be binding upon the Holder (and its permitted assigns) and the Company, including, without limitation, an amendment or waiver that is not agreed to by the Holder or that has an adverse effect on any or all holders of Warrants.

(m)  Severability . Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

(n)  Headings . The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

(o)  Force Majeure . Notwithstanding any provision herein to the contrary, the failure of any party to timely satisfy obligations hereunder shall be excused to the extent that (i) such failure follows the occurrence of a Force Majeure Event (defined below), and (ii) such Force Majeure Event has materially adversely affected the ability of such party (or its agents, including banks, transfer agents, and clearinghouses) to perform hereunder. A failure to perform shall be excused only for so long as the Force Majeure Event continues to materially adversely affect such person’s ability to perform. For purposes of this Section, “ Force Majeure Event ” shall mean the occurrence of any of the following events: (a) trading in securities generally on either the Nasdaq Stock Market or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the SEC or FINRA; (b) a general banking moratorium shall have been declared by any of federal, New York or California authorities; or (c) an act of war, terrorism or hostility shall have occurred, or (d) a strike, fire, flood, earthquake, accident or other calamity or Act of God shall have occurred.

** ** ** ** **

1

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

LA JOLLA PHARMACEUTICAL COMPANY

By:
Name: Deirdre Gillespie
Title: President and Chief Executive Officer

AGREED AND ACCEPTED:

[        ]

By:
Name:
Title:

NOTICE OF EXERCISE

TO: [        ]

1.         The undersigned hereby elects to purchase        Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

       The undersigned hereby elects to purchase        Warrant Shares of the Company pursuant to the terms of the net exercise provisions set forth in Section 1(c) of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any.

2.  Payment shall be made in lawful money of the United States.

3.  Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered by physical delivery of a certificate to:

4.  Accredited Investor . The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

2

ASSIGNMENT FORM
(To assign the foregoing warrant, execute
this form and supply required information.
Do not use this form to exercise the warrant.)

FOR VALUE RECEIVED, all [        ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

       whose address is

       .

Dated:        ,       

Holder’s Signature:

Holder’s Address:

Signature Guaranteed:       

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

3

EXECUTION COPY

CHIEF EXECUTIVE OFFICER EMPLOYMENT AGREEMENT

This Chief Executive Officer Employment Agreement (“ Agreement ”) is entered into as of May 24, 2010 by and between Deirdre Y. Gillespie, M.D. (“ Executive ”) and La Jolla Pharmaceutical Company, a Delaware corporation (the “ Company ”).

WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for her services; and

WHEREAS, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:

1.

Employment by the Company.

1.1 Title and Responsibilities . Subject to terms set forth herein, the Company agrees to employ Executive in the position of President and Chief Executive Officer and Executive hereby accepts such employment effective as of the date hereof (the “ Effective Date ”). During her employment with the Company, Executive will devote her best efforts and substantially all of her business time and attention (except for vacation periods as set forth herein and reasonable periods of illness or other incapacity permitted by the Company’s general employment policies) to the business of the Company.

1.2 Executive Position . Executive will continue to serve in an executive capacity and shall perform such duties as are customarily associated with her title, consistent with the bylaws of the Company and as reasonably required by the Board of Directors (the “ Board ”) of the Company.

1.3 Company Employment Policies . The employment relationship between the parties shall also be governed by the general employment policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that if the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control.

1.4 Board of Directors . On the Effective Date, Executive shall be confirmed as a member of the Company’s Board of Directors to serve until the next annual meeting of stockholders. Thereafter, she will stand for election with the other directors at the annual meeting of stockholders.

1.5 At-Will Employment . Executive’s relationship with the Company is at-will. The Company shall have the right to terminate Executive’s employment with the Company at any time with or without Cause and with or without notice.

2.

Compensation .

2.1 Base Salary . Executive shall receive for services to be rendered hereunder an initial annual Base Salary of $405,600, payable on a biweekly basis in accordance with the normal payroll practices of the Company (including deductions, withholdings and collections as required by law). Upon the closing of a Strategic Transaction (defined below), Executive’s annual Base Salary shall increase to $421,824 and such increase shall be retroactive to the Effective Date of this agreement. For purposes of this Agreement, “Strategic Transaction” shall have the meaning set forth in the Company’s Certificate of Incorporation. Executive will be considered for annual increases in base salary in accordance with Company policy and subject to review and approval by the Compensation Committee of the Board (the “ Compensation Committee”) starting with the annual performance review in January 2011

2.2 Bonus . Executive shall be eligible to participate in the Company’s executive level bonus plan throughout the duration of Executive’s employment with the Company.

(a)  Executive’s Performance . The amount of Executive’s bonus will depend upon Executive’s and the Company’s performance with respect to the goals to be established annually by the Compensation Committee.

(b)  Determination of Bonus . The amount of Executive’s bonus will be determined after the close of the Company’s fiscal year and paid out in the following year. To be eligible to receive a bonus, Executive must remain in employment with the Company throughout the entire fiscal year. Notwithstanding the foregoing, but subject to Section 2.3(c) below, in the event that Executive is terminated without Cause, as a result of a Constructive Termination or in connection with a Change in Control, the amount of Executive’s bonus, if any, will be determined after the occurrence of such event and will be paid to Executive promptly thereafter. In the case of a Change in Control, the Board agrees to consider whether to pay Executive a bonus.

(c)  No Guaranteed Bonus . Notwithstanding the foregoing, no bonus is guaranteed to Executive. Any bonus is subject to the approval of the Board, which retains the authority to review, grant, deny or revise any bonus in its sole discretion.

(d)  Target Bonus . The initial target bonus for Executive shall be fifty percent (50%) of her then current Base Salary.

(e)  Withholding . Any bonus paid to Executive shall be subject to such withholdings as may be required by law.

2.3 Stock Options . On the Effective Date, the Company will grant Executive options to purchase 4,000,000 shares of common stock of the Company (the “Initial Options ”) pursuant to the terms and subject to the conditions set forth in the La Jolla Pharmaceutical Company 2010 Equity Incentive Plan (the “Plan”). The Initial Option shall vest with respect to one thirty-sixth (1/36 ^th ) of the underlying shares monthly commencing on the Effective Date until all options are vested. The exercise price of the Initial Options shall be the Fair Market Value (as defined in the Plan) of the Company’s common stock on the Effective Date.

2.4. Standard Company Benefits and Vacation . Executive shall be entitled to those benefits provided to the Company’s executives generally, including healthcare benefits, and for which she is eligible pursuant to the terms and conditions of the relevant plans. Executive shall be entitled to four weeks of paid vacation per year.

2.5 Business Expenses . The Company shall promptly reimburse Executive for all reasonable and necessary business expenses incurred by Executive in connection with the business of the Company and the performance of her duties under this Agreement, subject to Executive providing the Company with reasonable documentation thereof.

3. Termination Of Employment .

3.1 Termination For Cause . If Executive is terminated for Cause, the Company shall pay Executive the Base Salary then in effect, prorated to the date of termination, and any amount earned buy not yet paid or otherwise due pursuant to Sections 2.2, 2.4 and 2.5 (collectively the “Standard Entitlements”). All other compensation from and after such termination shall cease (except for those benefits that must be continued pursuant to applicable law or by the terms of such benefit plans), and Executive shall not be entitled to any severance pay or other payment or compensation whatsoever upon such termination. If the Company terminates Executive for Cause, then all options to purchase Common Stock of the Company held by Executive as of the date of Executive’s termination, whether or not vested, shall immediately terminate and become unexercisable. For purposes of this Agreement, “ Cause ” is defined as the occurrence of one or more of the following: (i) Executive is convicted of or pleads guilty or nolo contendere to a felony or any crime involving moral turpitude, embezzlement or fraud; (ii) Executive breaches this Agreement or any Agreement entered into with the Company in a manner that materially and adversely affects the Company; (iii) Executive commits willful misconduct which materially and adversely impacts the Company; or (iv) Executive fails, after receipt of written notice and after receiving a period of at least 10 business days following such notice, to follow a legal direction of the Board; provided however , that if it is not possible to follow such direction within such 10 business day period, then Cause, in this case, shall mean the failure of Executive to follow a legal direction of the Board as soon as reasonably practicable after the end of such 10 business day period.

3.2 Termination Without Cause/Severance . If the Company terminates Executive’s employment without Cause, Executive will receive the Standard Entitlements and “Severance Benefits” as described in subsection 3.6 below provided that Executive complies with all severance conditions set forth in subsection 3.6(d) below.

3.3 Voluntary Resignation by Executive Due To Constructive Termination/Severance. If Executive voluntarily resigns Executive’s position with the Company at any time for Constructive Termination, Executive will receive the Standard Entitlements and “Severance Benefits” as described in subsection 3.6 below provided that Executive complies with all severance conditions set forth in subsection 3.6(d) below. For purposes of this Agreement, “ Constructive Termination ” shall mean any one of the following events which occurs on or after the Effective Date of this Agreement: (i) a material reduction in Executive’s responsibilities, authority or duties as an officer of the Company or a reduction in Executive’s title(s) as an officer of the Company; (ii) a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company and does not exceed 15%; (iii) a relocation of Executive’s office to a location outside of San Diego County, California; (iv) any material breach by the Company of its obligations under this Agreement; or (v) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company.

3.4 Termination Upon a Change in Control/Severance . If Executive’s employment is terminated by Company within twelve months after a Change of Control (as the term is defined below), other than for Cause (as defined in subsection 3.1 above), Executive shall be entitled to receive the “Severance Benefits” as described in subsection 3.6 below provided that Executive complies with all severance conditions set forth in subsection 3.6(d) below.

3.5 Voluntary Termination; Death or Disability .

(a)  Voluntary Termination . Executive may voluntarily terminate her employment with the Company at any time, after which no further compensation will be paid to Executive, except as specifically set forth herein. If Executive voluntary resigns, then all unvested options to purchase Common Stock of the Company held by Executive as of the date of Executive’s termination shall immediately terminate and become unexercisable and all vested options held by Executive shall remain exercisable until three months after the date of cessation of service, in the case of incentive stock options, or six months after the date of cessation of service, in the case of non-qualified stock options.

(b)  Death or Disability . The Executive’s employment under this Agreement shall terminate immediately and without notice by the Company upon the death or disability of the Executive. For purposes of this Agreement, Executive will be deemed to have a disability if she becomes physically or mentally incapacitated or disabled or otherwise unable to fully discharge her duties hereunder for a period of 60 consecutive calendar days or for 120 days in any 360-day period. If Executive’s employment ceases as a result of death or disability, then all unvested options to purchase Common Stock of the Company held by Executive shall immediately terminate and become unexercisable and all vested options held by Executive shall remain exercisable until the one year anniversary of the date of cessation of service.

(c)  No Severance Pay . In the event of Executive’s death or disability or if Executive voluntarily terminates her employment other than due to a Constructive Termination, she will not be entitled to severance pay, pay in lieu of notice or any other such compensation.

3.6 Severance Benefits. Effective immediately after the closing of a Strategic Transaction (defined above), if the Company terminates Executive’s employment without Cause or if Executive terminates her employment due to a Constructive Termination, Executive shall be entitled to the following:

(a)  Severance Payment . Executive shall be entitled to a lump sum severance payment equal to 18 months of Executive’s then current annual Base Salary (the " Standard Severance Payment”) but in no event less than the annual Base Salary of $405,600, payable upon effectiveness of the Release Agreement.

(b)  Stock Options . All of Executive’s then outstanding Options will immediately vest and become exercisable and all Executive’s vested Options shall expire on the 18 month anniversary of the termination date. Notwithstanding the foregoing, in no event shall any Option be exercisable after the date of expiration set forth in the Plan.

(c)  Healthcare Coverage . To the extent that Executive is eligible to continue her medical coverage under COBRA, the Company will pay the premiums for Executive’s COBRA coverage as they become due (including the premiums for any dependent coverage she elects), until the earlier of: (i) the date Executive accepts full time employment and/or becomes covered under another plan; (ii) the date she is otherwise no longer eligible for COBRA coverage; or (iii) 18 months after the effective date of separation. If coverage under COBRA is not available to the Company, then Company shall pay Executive an amount equivalent to the premiums it would have paid for Executive’s COBRA coverage.

(d)  Conditions to Receive Severance Benefits . The Severance Benefits pursuant to subsections 3.6 (a), (b) and (c) will be paid, provided that Executive timely executes and delivers a Release Agreement to the Company,

(e)  Section 409A . Notwithstanding any provision of this Agreement to the contrary, if, at the time of Executive’s termination of employment with the Company, Executive is a “specified employee” as defined in Section 409A of the Internal Revenue Code (the “Code”), and one or more of the payments or benefits received or to be received by Executive pursuant to this Agreement or otherwise would constitute deferred compensation subject to Section 409A, then:

(i) No such payment will be made under this Agreement until the earlier of (A) the date which is six months and one day after her “separation from service” or (B) the date of Executive’s “death”.

(ii) For the sake of clarity, the provisions of this Section 5.3(e) only apply to the extent required to avoid Executive’s incurrence of any penalty tax or interest under Section 409A of the Code or any regulations or United States Treasury guidance promulgated thereunder. In addition, if any provision of this Agreement would cause Executive to incur any penalty tax or interest under Section 409A of the Code or any regulations or Treasury guidance promulgated thereunder, the Company may reform such provision to maintain to the maximum extent practicable the original intent of the applicable provision without violating the provisions of Section 409A of the Code.

3.7 Cessation . If Executive violates any provision of Sections 5, 6, 7 or 8 of this Agreement, any severance payments or other benefits being provided to Executive will cease immediately, and Executive will not be entitled to any further compensation from the Company.

4.  Change in Control. “ Change in Control ” means the following and shall be deemed to occur if any of the following events occur:

(a) Except as provided by subsection (iii) hereof, the acquisition (other than from the Company) by any person, entity or “group,” within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of forty percent (40%) or more of either the then outstanding shares of common stock or the combined voting power of the Company’s then outstanding voting securities entitled to vote generally in the election of directors; or

(b) Individuals who, as of the effective date of the Plan, constitute the Board (the " Incumbent Board ”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the date hereof whose election, or nomination for election by the Company’s stockholders, is or was approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of the Company, as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) shall be, for purposes of the Plan, considered as though such person were a member of the Incumbent Board; or

(c) Approval by the stockholders of the Company of a reorganization, merger or consolidation with any other person, entity or corporation, other than:

(i) a merger or consolidation which would result in the persons holding the voting securities of the Company outstanding immediately prior thereto continuing to hold more than fifty percent (50%) of the combined voting power of the voting securities of the Company or its successor which are outstanding immediately after such merger or consolidation, or

(ii) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no person acquires forty percent (40%) or more of the combined voting power of the Company’s then outstanding voting securities; or

(d) Approval by the stockholders of the Company of a plan of complete liquidation of the Company or an agreement for the sale or other disposition by the Company of all or substantially all of the Company’s assets.

(e) Any other transaction that is reasonably deemed a change of control by a majority of the independent Board members.

Notwithstanding the foregoing, a Change in Control shall not be deemed to have occurred (1) if the “person” is an underwriter or underwriting syndicate that has acquired the ownership of 50% or more of the combined voting power of the Company’s then outstanding voting securities solely in connection with a public offering of the Company’s securities, or (2) if the “person” is an employee stock ownership plan or other employee benefit plan maintained by the Company that is qualified under the provisions of the Employee Retirement Income Security Act of 1974, as amended.

5. Confidential Information, Rights and Duties .

5.1 Agreement .

(a) Confidential Information .

(i) Executive specifically agrees that she shall not at any time, either during or subsequent to the term of her employment with the Company, in any fashion, form or manner, either directly or indirectly, unless expressly consented to in writing by an executive officer of the Company, use, divulge, disclose or communicate to any person or entity any confidential information of any kind, nature or description concerning any matters affecting or relating to the business of the Company. The parties to this Agreement hereby stipulate that, as between them, the above information and items are important, material and confidential trade secrets that affect the successful conduct of the Company’s business and its goodwill, and that any breach of any term of this section is a material breach of this Agreement. All equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists or other written and graphic records, and the like, including tangible or intangible computer programs, records and data, affecting or relating to the business of the Company, which the Executive might prepare, use, construct, observe, posses or control, shall be and shall remain the Company’s sole property.

(ii) For purposes of this Agreement, the term “confidential information” shall not include any information that: (A) has been made public by the Company (other than by acts or omissions of Executive in violation of this Agreement or other obligation of confidentiality); (B) is developed by Executive independently of any information the Executive learns in the course of fulfilling her duties hereunder; or (C) Executive is legally compelled to disclose; provided that (1) Executive is advised by written opinion of the Executive’s counsel, who shall be reasonably satisfactory to the Company, that she is legally required to disclose such information and (2) Executive notifies the Company of such proposed disclosure as far in advance of its disclosure as is practicable and uses her best efforts to obtain assurances that confidential treatment will be accorded to such information.

(b)  Non-Interference . Any wrongful interference with the Company’s business, property, confidential information, trade secrets, clients, customers, employees or independent contractors by Executive or any of Executive’s agents during or after the term of Executive’s employment shall be treated and acknowledged by the parties as a material breach of this Agreement. If such interference occurs at a time that Executive is employed by the Company, such interference shall be grounds for the Company to terminate Executive for Cause.

5.2 Remedies . Executive’s duties under this Section 3 shall survive termination of Executive’s employment with the Company. Executive acknowledges that a remedy at law for any breach or threatened breach by Executive of the provisions of this Section 3 would be inadequate, and Executive therefore agrees that the Company shall be entitled to injunctive relief in case of any such breach or threatened breach.

6. Outside Activities .

6.1 Activities . Except as set forth on Exhibit A hereto or with the prior written consent of the Board, Executive will not during her employment with the Company undertake or engage in any other employment, occupation or business enterprise (other than enterprises in which Executive is a passive investor; provided that such passive investment is consistent with this terms of this Agreement, including this Section 4). Notwithstanding the foregoing, Executive may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of her duties hereunder and are otherwise consistent with this Section 4.

6.2 Investments and Interests . Executive agrees not to acquire, assume or participate in, directly or indirectly, any material position, investment or interest known by her to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.

6.3 Non-Competition .

(a) During her employment by the Company, except on behalf of the Company, Executive will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever which were known by her to

compete directly with the Company, throughout the world, in any line of business engaged in (or planned to be engaged in) by the Company.

(b) Notwithstanding the foregoing, nothing in this Agreement shall prevent Executive from owning for passive investment purposes less than 1% of the publicly traded common equity securities of any company engaged in the business of the Company (so long as Executive has no power to manage, operate, advise, consult with or control the competing enterprise and no power, alone or in conjunction with other affiliated parties, to select a director, manager, general partner, or similar governing official of the competing enterprise other than in connection with the normal and customary voting powers afforded Executive in connection with any permissible equity ownership).

7.  Other Agreements .

7.1 Employees . For one years immediately following the termination date of Executive’s employment for any reason, Executive agrees not to solicit, attempt to solicit, induce, or otherwise cause any employee of the Company to terminate his or her employment in order to become an employee, consultant or independent contractor to or for any competitor of the Company.

7.2 Noninterference . For one year immediately following the termination date of Executive’s employment for any reason, Executive agrees not to solicit, on Executive’s own behalf or for any entity that is in competition with the Company, any person or entity that is doing business with the Company or is an active prospect to do business with the Company for the purpose of diverting Company’s business or active business opportunities in competition with Company.

8.  Release . In exchange for the benefits and other consideration under this Agreement to which Executive would not otherwise be entitled, Executive shall enter into and execute a release substantially in the form attached hereto as Exhibit B (the “Release Agreement ”) upon her termination of employment. Unless the Release Agreement is executed by Executive and delivered to the Company within 21 days after the termination of Executive’s employment with the Company, and the same is not revoked, Executive shall not receive any severance benefits provided under this Agreement.

9. General Provisions.

9.1 Notices . Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile transmission) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at her address as listed on the Company payroll.

9.2 Severability . Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein or therein.

9.3 Waiver . If either party should waive any breach of any provisions of this Agreement, she or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

9.4 Complete Agreement . This Agreement, together with the exhibits attached hereto and incorporated herein, constitutes the entire agreement between Executive and the Company and it is the complete, final, and exclusive embodiment of their agreement and supersedes any prior agreement written or otherwise between Executive and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation other than those expressly contained herein or therein, and it cannot be modified or amended except in a writing signed by an officer of the Company.

9.5 Counterparts . This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same agreement or plan. Signatures transmitted electronically or via facsimile shall be deemed to be original signatures.

9.6 Headings . The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof or thereof nor to affect the meaning thereof.

9.7 Successors and Assigns . This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of her duties hereunder and she may not assign any of her rights hereunder without the written consent of the Company.

9.8 Arbitration . To provide a mechanism for rapid and economical dispute resolution, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to this Agreement (including the Release Agreement) and its enforcement, performance, breach, or interpretation, will be resolved, to the fullest extent permitted by law, by final, binding, and confidential arbitration before a single arbitrator held in San Diego, California and conducted by Judicial Arbitration & Mediation

Services/Endispute (“ JAMS ”), under its then-existing Rules and Procedures. The parties shall be entitled to conduct adequate discovery, and they may obtain all remedies available to the parties as if the matter had been tried in court. The arbitrator shall issue a written decision which specifies the findings of fact and conclusions of law on which the arbitrator’s decision is based. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof. Unless otherwise required by law, the arbitrator will award reasonable expenses (including reimbursement of the assigned arbitration costs) to the prevailing party. Nothing in this Section 9.8 or in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in a court of competent jurisdiction to prevent irreparable harm pending the conclusion of any such arbitration.

9.9 Governing Law . All questions concerning the construction, validity and

interpretation of this Agreement will be governed by the law of the State of California as applied to contracts made and to be performed entirely within California, excluding the rules on conflicts of law.

IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first above written.

LA JOLLA PHARMACEUTICAL COMPANY

By: /s/ Craig R. Smith, M.D.

EXECUTIVE

By: /s/ Deirdre Y. Gillespie

1

EXHIBIT A

1.

The Communications Strategy Group Inc., Advisory Board Member and Senior Medical Adviser

2

EXHIBIT B
RELEASE AGREEMENT

I understand that all of my positions with La Jolla Pharmaceutical Company and its subsidiaries and affiliates (collectively, the “ Company ”) terminated effective

(the “ Separation Date ”). The Company has agreed that if I choose to sign this Agreement, the Company will pay me severance benefits (minus the standard withholdings and deductions) pursuant to the terms of the Chief Executive Officer Employment Agreement entered into as of May 24, 2010 between myself and the Company (the “ Employment Agreement ”). I understand that I am not entitled to any severance payment under the Employment Agreement unless I sign this release agreement. I understand that in addition to this severance, the Company will pay me all of my accrued salary and vacation, to which I am entitled by law regardless of whether I sign this release agreement.

In consideration for the severance payment I am to receive under my Employment Agreement, I agree not to use or disclose any of the Company’s proprietary information without written authorization from an executive officer of the Company, to immediately return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control, and to release the Company and its current and former officers, directors, agents, attorneys, employees, stockholders, and affiliates from any and all claims, liabilities, demands, causes of action, attorneys’ fees, damages, or obligations of every kind and nature, whether they are known or unknown, arising at any time prior to the date I sign this release agreement. This general release includes, but is not limited to: all federal and state statutory and common law claims, claims related to my employment or the termination of my employment or related to breach of contract, tort, wrongful termination, discrimination, wages or benefits, or claims for any form of compensation. This release is not intended to release any claims I have or may have against any of the released parties for (a) indemnification as a director, officer, agent or employee under applicable law, charter document or agreement, (b) severance and other termination benefits specifically provided for in my employment agreement which constitutes a part of the consideration for this release, (c) health or other insurance benefits based on claims already submitted or which are covered claims properly submitted in the future, (d) vested rights under pension, retirement or other benefit plans, or (e) in respect of events, acts or omissions occurring after the date of this release agreement.

In releasing claims unknown to me at present, I am waiving all rights and benefits under Section 1542 of the California Civil Code, and any law or legal principle of similar effect in any jurisdiction: “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by her must have materially affected her settlement with the debtor.”

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the federal Age Discrimination in Employment Act of 1967, as amended (the “ADEA”). I have been advised by this writing, as required by the ADEA that: (a) my waiver and release do not apply to any claims that may arise after my signing of this release; (b) I should consult with an attorney prior to executing this release, (c) I have 21 days within

which to consider this release (although I may choose to voluntarily execute this release earlier); (d) I have seven days following the execution of this release to revoke it; and (e) this release will not be effective until the eighth day after this release agreement has been signed both by me and by the Company (“ Effective Date ”).

This release agreement constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by or on behalf of the Company that is not expressly stated herein. This release agreement may only be modified by a writing signed by both me and a duly authorized officer of the Company.

I accept and agree to the terms and conditions stated above:

By:

Date:

ACKNOWLEDGED:
LA JOLLA PHARMACEUTICAL COMPANY
By:
Name:
Title:
Date:

3

CONFIDENTIAL RETENTION AGREEMENT

This Confidential Retention Agreement (“Agreement”) is made by and between La Jolla Pharmaceutical Company (“LJPC”) and Deirdre Y. Gillespie M.D. (“Gillespie”) with respect to the following facts:

A. Gillespie is currently employed by LJPC as the President and Chief Executive Officer pursuant to a Chief Executive Officer Employment Agreement dated March 15, 2006 and Amendment to Chief Executive Officer Employment Agreement dated July 31, 2007 and Amendment to Chief Executive Officer Employment Agreement dated December 31, 2008 (collectively referred to as “Employment Agreement”), which provides for severance in exchange for a release of all claims, in the event Gillespie’s employment is involuntarily terminated without Cause.

B. Due to the negative result of LJPC’s clinical trial, LJPC is considering a merger, liquidation, financing or other transaction (the “Transaction”).

C. LJPC and Gillespie previously entered into a Confidential Retention and Separation Agreement and General Release of All Claims (the “Prior Agreement”) dated December 12, 2009, which by its terms expired on March 31, 2010. The Prior Agreement provided for a Retention Bonus of $202,800.00 payable on execution of that Agreement and a severance payment ($405,600.00) upon the earlier of Gillespie’s involuntary termination of employment or March 31, 2010. Such severance payment under the Prior Agreement were structured so as to be exempt from application of Internal Revenue Code Section 409A.

D. LJPC and Gillespie confirm that Gillespie’s Retention Bonus of $202,800.00 paid in December 2009 was earned on March 31, 2010, and that her severance payment of $405,600.00 was in effect a Retention Bonus and was earned on March 31, 2010 and is now payable.

E. LJPC and Gillespie confirm that Gillespie was not terminated on March 31, 2010 and Gillespie’s employment with LJPC will be extended until the first to occur of (1) the closing of a Transaction, (2) an involuntary termination of employment without cause, .(3) July 31, 2010

F. In order to retain Gillespie’s services, the parties wish to supersede the severance provisions of the Employment Agreement and the Prior Agreement and proceed in accordance with the terms and conditions in this Agreement.

G. The parties desire to settle all claims and issues that have, or could have been raised, in relation to Gillespie’s employment with LJPC and arising out of or in any way related to the acts, transactions or occurrences between Gillespie and LJPC to date, including, but not limited to, Gillespie’s employment with LJPC or the termination of that employment, on the terms set forth below.

THEREFORE, in consideration of the promises and agreements hereinafter set forth, it is agreed by and between the undersigned as follows:

1. Severance Payment . LJPC agrees to pay Gillespie her severance payment of $405,600.00, less all legally required payroll deductions and withholdings, payable in a lump sum on the first regular pay day following the Effective Date of this Agreement.

2. Retention Bonus . LJPC agrees to pay Gillespie a Retention Bonus to retain her services for the additional term. The amount of this Retention Bonus will be determined as follows:

•

$152,100.00 should the company determine to dividend the Company’s remaining cash to stockholders

•

$202,800.00 should the Company secure additional funding or be acquired by another company

•

$405,600.00 should the Company secure a product partnership with related financing

The Retention Bonus, less all legally required payroll deductions and withholdings (“Retention Bonus”), is payable in a lump sum on the first regular pay day following the date on which the Board of Directors confirms that one of the events described above has occurred.

3.  General Release . Gillespie unconditionally, irrevocably and absolutely releases and discharges LJPC, and any parent and subsidiary corporations, divisions and affiliated corporations, partnerships or other affiliated entities of LJPC, past and present, as well as LJPC’s employees, officers, directors, agents, successors and assigns (collectively, “Released Parties”), from all claims related in any way to Employment Agreement and all transactions or occurrences between them to date, to the fullest extent permitted by law, including, but not limited to, Gillespie’s employment with LJPC, the termination of Gillespie’s employment, and all other losses, liabilities, claims, charges, demands and causes of action, known or unknown, suspected or unsuspected, arising directly or indirectly out of or in any way connected with Gillespie’s employment with LJPC. This general release is intended to have the broadest possible application and includes, but is not limited to, any tort, contract, common law, constitutional or other statutory claims, including, but not limited to alleged violations of the California Labor Code or the federal Fair Labor Standards Act, Title VII of the Civil Rights Act of 1964 and the California Fair Employment and Housing Act, the Americans with Disabilities Act, the Age Discrimination in Employment Act of 1967, as amended, and all claims for attorneys’ fees, costs and expenses. Gillespie expressly waives Gillespie’s right to recovery of any type, including damages or reinstatement, in any administrative or court action, whether state or federal, and whether brought by Gillespie or on Gillespie’s behalf, related in any way to the matters released herein. However, this general release is not intended to bar any claims that, by statute, may not be waived, such as claims for workers’ compensation benefits, unemployment insurance benefits, statutory indemnity, and any challenge to the validity of Gillespie’s release of claims under the Age Discrimination in Employment Act of 1967, as amended, as set forth in this Agreement.

3. California Civil Code Section 1542 Waiver . Gillespie expressly acknowledges and agrees that all rights under Section 1542 of the California Civil Code are expressly waived. That section provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

4. Representation Concerning Filing of Legal Actions . Gillespie represents that, as of the date of this Agreement, she has not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against LJPC or any of the other Released Parties in any court or with any governmental agency.

5. Nondisparagement . Gillespie agrees that she will not make any voluntary statements, written or oral, or cause or encourage others to make any such statements that defame, disparage or in any way criticize the personal and/or business reputations, practices or conduct of LJPC or any of the other Released Parties.

6. Confidentiality and Return of LJPC Property . By signing this Agreement, Gillespie represents and warrants that Gillespie has, or will, return to LJPC on or before the Separation Date, all LJPC property, data and information belonging to LJPC and agrees not use or disclose to others any confidential or proprietary information of LJPC or the Released Parties.

7. Continuing Obligations . Gillespie further agrees to comply with the continuing obligations regarding confidentiality set forth in the surviving provisions of the Invention and Confidential Information Agreement signed by Gillespie.

8. No Admissions . By entering into this Agreement, the Released Parties make no admission that they have engaged, or are now engaging, in any unlawful conduct. The parties understand and acknowledge that this Agreement is not an admission of liability and shall not be used or construed as such in any legal or administrative proceeding.

9. Older Workers’ Benefit Protection Act . This Agreement is intended to satisfy the requirements of the Older Workers’ Benefit Protection Act, 29 U.S.C. sec. 626(f). Gillespie, by this Agreement, is advised to consult with an attorney before executing this Agreement.

9.1 Acknowledgments/Time to Consider . Gillespie acknowledges and agrees that the Retention Bonus is a sum to which she is not otherwise entitled absent the signing of this Agreement; (b) Gillespie has read and understands the terms of this Agreement; (c) Gillespie has been advised in writing to consult with an attorney before executing this Agreement; (d) Gillespie has obtained and considered such legal counsel as she deems necessary; (e) Gillespie has been given twenty-one (21) days to consider whether or not to enter into this Agreement (although she may elect not to use the full 21-day period at her option); and (f) by signing this Agreement, Gillespie acknowledges that she does so freely, knowingly, and voluntarily.

9.2 Revocation/Effective Date . This Agreement shall not become effective or enforceable until the eighth day after Gillespie signs this Agreement. In other words, she may revoke her acceptance of this Agreement within seven (7) days after the date she signs it. Gillespie’s revocation must be in writing and received by Craig R. Smith M.D., Chairman, Board of Directors, by 5:00 p.m. Pacific Time on the seventh day in order to be effective. If Gillespie does not revoke acceptance within the seven (7) day period, her acceptance of this Agreement shall become binding and enforceable on the eighth day (“Effective Date”). The Severance Payment shall become due and payable in accordance with paragraph 1, provided this Agreement has not been revoked.

9.3 Preserved Rights of Gillespie . This Agreement does not waive or release any rights or claims that Gillespie may have under the Age Discrimination in Employment Act that arise after the execution of this Agreement. In addition, this Agreement does not prohibit Gillespie from challenging the validity of this Agreement’s waiver and release of claims under the Age Discrimination in Employment Act of 1967, as amended.

10. Full Defense. This Agreement may be pled as a full and complete defense to, and may be used as a basis for an injunction against, any action, suit or other proceeding that may be prosecuted, instituted or attempted by Gillespie in breach hereof.

11. Severability . In the event any provision of this Agreement shall be found unenforceable, the unenforceable provision shall be deemed deleted and the validity and enforceability of the remaining provisions shall not be affected thereby.

12. Applicable Law . The validity, interpretation and performance o f this Agree ment shall be construed and interpreted according to the laws of the United States of America and the State of California.

13. Entire Agreement; Modification . This Agreement and the surviving provisions of the Invention and Confidential Information Agreement previously executed by Gillespie, is intended to be the entire agreement between the parties and supersedes and cancels any and all other and prior agreements, written or oral, between the parties regarding this subject matter. Except as expressly amended hereby, all other terms and provision of the Employment Agreement shall remain in full force and effect. This Agreement may be amended only by a written instrument executed by all parties hereto.

THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATES SHOWN BELOW.

Dated: May 24, 2010
By: /s/ Deirdre Y. Gillespie
Deirdre Y. Gillespie M.D.
LA JOLLA PHARMACEUTICAL COMPANY

Dated: May 24, 2010
By: /s/ Craig R. Smith M.D.
Craig R. Smith M.D.
Chairman of the Board

EXECUTION COPY

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (“ Agreement ”) is entered into as of May 24, 2010 by and between Gail A. Sloan (“ Executive ”) and La Jolla Pharmaceutical Company, a Delaware corporation (the “ Company ”).

WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for her services; and

WHEREAS, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:

1.

Employment by the Company.

1.1 Title and Responsibilities . Subject to terms set forth herein, the Company agrees to employ Executive in the position of Chief Financial Officer and Executive hereby accepts such employment effective as of the date hereof (the “ Effective Date ”). During her employment with the Company, Executive will devote her best efforts and substantially all of her business time and attention (except for vacation periods as set forth herein and reasonable periods of illness or other incapacity permitted by the Company’s general employment policies) to the business of the Company.

1.2 Executive Position . Executive will continue to serve in an executive capacity and shall perform such duties as are customarily associated with her title, consistent with the bylaws of the Company and as reasonably required by the Board of Directors (the “ Board ”) of the Company.

1.3 Company Employment Policies . The employment relationship between the parties shall also be governed by the general employment policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that if the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control.

1.4 At-Will Employment . Executive’s relationship with the Company is at-will. The Company shall have the right to terminate Executive’s employment with the Company at any time with or without Cause and with or without notice.

2.

Compensation .

2.1 Base Salary . Executive shall receive for services to be rendered hereunder an initial annual Base Salary of $198,551, payable on a biweekly basis in accordance with the normal payroll practices of the Company (including deductions, withholdings and collections as required by law). Upon the closing of a Strategic Transaction (defined below), Executive’s annual Base Salary shall increase to $206,493 and such increase shall be retroactive to the Effective Date of this agreement. For purposes of this Agreement, “Strategic Transaction” shall have the meaning set forth in the Company’s Certificate of Incorporation. Executive will be considered for annual increases in base salary in accordance with Company policy and subject to review and approval by the Compensation Committee of the Board (the “ Compensation Committee”) starting with the annual performance review in January 2011.

2.2 Bonus . Executive shall be eligible to participate in the Company’s executive level bonus plan throughout the duration of Executive’s employment with the Company.

(a)  Executive’s Performance . The amount of Executive’s bonus will depend upon Executive’s and the Company’s performance with respect to the goals to be established annually by the Compensation Committee.

(b)  Determination of Bonus . The amount of Executive’s bonus will be determined after the close of the Company’s fiscal year and paid out in the following year. To be eligible to receive a bonus, Executive must remain in employment with the Company throughout the entire fiscal year. Notwithstanding the foregoing, but subject to Section 2.3(c) below, in the event that Executive is terminated without Cause, as a result of a Constructive Termination or in connection with a Change in Control, the amount of Executive’s bonus, if any, will be determined after the occurrence of such event and will be paid to Executive promptly thereafter.

(c)  No Guaranteed Bonus . Notwithstanding the foregoing, no bonus is guaranteed to Executive. Any bonus is subject to the approval of the Board, which retains the authority to review, grant, deny or revise any bonus in its sole discretion.

(d)  Target Bonus . The initial target bonus for Executive shall be thirty-five percent (35%) of her then current Base Salary.

(e)  Withholding . Any bonus paid to Executive shall be subject to such withholdings as may be required by law.

2.3 Stock Options . On the Effective Date, the Company will grant Executive options to purchase 1,800,000 shares of common stock of the Company (the “Initial Options ”) pursuant to the terms and subject to the conditions set forth in the La Jolla Pharmaceutical Company 2010 Equity Incentive Plan (the “Plan”). The Initial Option shall vest with respect to one thirty-sixth (1/36 ^th ) of the underlying shares monthly commencing on the Effective Date until all options are vested. The exercise price of the Initial Options shall be the Fair Market Value (as defined in the Plan) of the Company’s common stock on the Effective Date.

2.4. Standard Company Benefits and Vacation . Executive shall be entitled to those benefits provided to the Company’s executives generally, including healthcare benefits, and for which she is eligible pursuant to the terms and conditions of the relevant plans. Executive shall be entitled to four weeks of paid vacation per year.

2.5 Business Expenses . The Company shall promptly reimburse Executive for all reasonable and necessary business expenses incurred by Executive in connection with the business of the Company and the performance of her duties under this Agreement, subject to Executive providing the Company with reasonable documentation thereof.

3. Termination Of Employment .

3.1 Termination For Cause . If Executive is terminated for Cause, the Company shall pay Executive the Base Salary then in effect, prorated to the date of termination, and any amount earned buy not yet paid or otherwise due pursuant to Sections 2.2, 2.4 and 2.5 (collectively the “Standard Entitlements”). All other compensation from and after such termination shall cease (except for those benefits that must be continued pursuant to applicable law or by the terms of such benefit plans), and Executive shall not be entitled to any severance pay or other payment or compensation whatsoever upon such termination. If the Company terminates Executive for Cause, then all options to purchase Common Stock of the Company held by Executive as of the date of Executive’s termination, whether or not vested, shall immediately terminate and become unexercisable. For purposes of this Agreement, “ Cause ” is defined as the occurrence of one or more of the following: (i) Executive is convicted of or pleads guilty or nolo contendere to a felony or any crime involving moral turpitude, embezzlement or fraud; (ii) Executive breaches this Agreement or any Agreement entered into with the Company in a manner that materially and adversely affects the Company; (iii) Executive commits willful misconduct which materially and adversely impacts the Company; or (iv) Executive fails, after receipt of written notice and after receiving a period of at least 10 business days following such notice, to follow a legal direction of the Board; provided however , that if it is not possible to follow such direction within such 10 business day period, then Cause, in this case, shall mean the failure of Executive to follow a legal direction of the Board as soon as reasonably practicable after the end of such 10 business day period.

3.2 Termination Without Cause/Severance . If the Company terminates Executive’s employment without Cause, Executive will receive the Standard Entitlements and “Severance Benefits” as described in subsection 3.6 below provided that Executive complies with all severance conditions set forth in subsection 3.6(d) below.

3.3 Voluntary Resignation by Executive Due To Constructive Termination/Severance. If Executive voluntarily resigns Executive’s position with the Company at any time for Constructive Termination, Executive will receive the Standard Entitlements and “Severance Benefits” as described in subsection 3.6 below provided that Executive complies with all severance conditions set forth in subsection 3.6(d) below. For purposes of this Agreement, “ Constructive Termination ” shall mean any one of the following events which occurs on or after the Effective Date of this Agreement: (i) a material reduction in Executive’s responsibilities, authority or duties as an officer of the Company or a reduction in Executive’s title(s) as an officer of the Company without the written consent of the Executive; (ii) a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company and does not exceed 15%; (iii) a relocation of Executive’s office to a location outside of San Diego County, California; (iv) any material breach by the Company of its obligations under this Agreement; or (v) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company.

3.4 Termination Upon a Change in Control/Severance . If Executive’s employment is terminated by Company within twelve months after a Change of Control (as the term is defined below), other than for Cause (as defined in subsection 3.1 above), Executive shall be entitled to receive the “Severance Benefits” as described in subsection 3.6 below provided that Executive complies with all severance conditions set forth in subsection 3.6(d) below.

3.5 Voluntary Termination; Death or Disability .

(a)  Voluntary Termination . Executive may voluntarily terminate her employment with the Company at any time, after which no further compensation will be paid to Executive, except as specifically set forth herein. If Executive voluntary resigns, then all unvested options to purchase Common Stock of the Company held by Executive as of the date of Executive’s termination shall immediately terminate and become unexercisable and all vested options held by Executive shall remain exercisable until three months after the date of cessation of service, in the case of incentive stock options, or six months after the date of cessation of service, in the case of non-qualified stock options .

(b)  Death or Disability . The Executive’s employment under this Agreement shall terminate immediately and without notice by the Company upon the death or disability of the Executive. For purposes of this Agreement, Executive will be deemed to have a disability if she becomes physically or mentally incapacitated or disabled or otherwise unable to fully discharge her duties hereunder for a period of 60 consecutive calendar days or for 120 days in any 360-day period. If Executive’s employment ceases as a result of death or disability, then all unvested options to purchase Common Stock of the Company held by Executive shall immediately terminate and become unexercisable and all vested options held by Executive shall remain exercisable until the one year anniversary of the date of cessation of service.

(c)  No Severance Pay . In the event of Executive’s death or disability or if Executive voluntarily terminates her employment other than due to a Constructive Termination, she will not be entitled to severance pay, pay in lieu of notice or any other such compensation.

3.6 Severance Benefits. Effective immediately after the closing of a Strategic Transaction (defined above), if the Company terminates Executive’s employment without Cause or if Executive terminates her employment due to a Constructive Termination, Executive shall be entitled to the following:

(a)  Severance Payment . Executive shall be entitled to a lump sum severance payment equal to one year of Executive’s then current annual Base Salary (the " Standard Severance Payment”) but in no event less than the annual Base Salary of $198,551, payable upon effectiveness of the Release Agreement.

(b)  Stock Options . All of Executive’s then outstanding Options will immediately vest and become exercisable and all Executive’s vested Options shall expire on the one year anniversary of the termination date. Notwithstanding the foregoing, in no event shall any Option be exercisable after the date of expiration set forth in the Plan.

(c)  Healthcare Coverage . To the extent that Executive is eligible to continue her medical coverage under COBRA, the Company will pay the premiums for Executive’s COBRA coverage as they become due (including the premiums for any dependent coverage she elects), until the earlier of: (i) the date Executive accepts full time employment and/or becomes covered under another plan; (ii) the date she is otherwise no longer eligible for COBRA coverage; or (iii) 12 months after the effective date of separation. If coverage under COBRA is not available to the Company, then Company shall pay Executive an amount equivalent to the premiums it would have paid for Executive’s COBRA coverage.

(d)  Conditions to Receive Severance Benefits . The Severance Benefits pursuant to subsections 3.6 (a), (b) and (c) will be paid, provided that Executive timely executes and delivers a Release Agreement to the Company,

(e)  Section 409A . Notwithstanding any provision of this Agreement to the contrary, if, at the time of Executive’s termination of employment with the Company, Executive is a “specified employee” as defined in Section 409A of the Internal Revenue Code (the “Code”), and one or more of the payments or benefits received or to be received by Executive pursuant to this Agreement or otherwise would constitute deferred compensation subject to Section 409A, then:

(i) No such payment will be made under this Agreement until the earlier of (A) the date which is six months and one day after her “separation from service” or (B) the date of Executive’s “death”.

(ii) For the sake of clarity, the provisions of this Section 5.3(e) only apply to the extent required to avoid Executive’s incurrence of any penalty tax or interest under Section 409A of the Code or any regulations or United States Treasury guidance promulgated thereunder. In addition, if any provision of this Agreement would cause Executive to incur any penalty tax or interest under Section 409A of the Code or any regulations or Treasury guidance promulgated thereunder, the Company may reform such provision to maintain to the maximum extent practicable the original intent of the applicable provision without violating the provisions of Section 409A of the Code.

3.7 Cessation . If Executive violates any provision of Sections 5, 6, 7 or 8 of this Agreement, any severance payments or other benefits being provided to Executive will cease immediately, and Executive will not be entitled to any further compensation from the Company.

4.  Change in Control. " Change in Control ” means the following and shall be deemed to occur if any of the following events occur:

(a) Except as provided by subsection (iii) hereof, the acquisition (other than from the Company) by any person, entity or “group,” within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of forty percent (40%) or more of either the then outstanding shares of common stock or the combined voting power of the Company’s then outstanding voting securities entitled to vote generally in the election of directors; or

(b) Individuals who, as of the effective date of the Plan, constitute the Board (the " Incumbent Board ”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the date hereof whose election, or nomination for election by the Company’s stockholders, is or was approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of the Company, as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) shall be, for purposes of the Plan, considered as though such person were a member of the Incumbent Board; or

(c) Approval by the stockholders of the Company of a reorganization, merger or consolidation with any other person, entity or corporation, other than:

(i) a merger or consolidation which would result in the persons holding the voting securities of the Company outstanding immediately prior thereto continuing to hold more than fifty percent (50%) of the combined voting power of the voting securities of the Company or its successor which are outstanding immediately after such merger or consolidation, or

(ii) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no person acquires forty percent (40%) or more of the combined voting power of the Company’s then outstanding voting securities; or

(d) Approval by the stockholders of the Company of a plan of complete liquidation of the Company or an agreement for the sale or other disposition by the Company of all or substantially all of the Company’s assets; or

(e) Any other transaction that is reasonably deemed a change of control by a majority of the independent Board members.

Notwithstanding the foregoing, a Change in Control shall not be deemed to have occurred (1) if the “person” is an underwriter or underwriting syndicate that has acquired the ownership of 50% or more of the combined voting power of the Company’s then outstanding voting securities solely in connection with a public offering of the Company’s securities, or (2) if the “person” is an employee stock ownership plan or other employee benefit plan maintained by the Company that is qualified under the provisions of the Employee Retirement Income Security Act of 1974, as amended.

5. Confidential Information, Rights and Duties .

5.1 Agreement .

(a) Confidential Information .

(i) Executive specifically agrees that she shall not at any time, either during or subsequent to the term of her employment with the Company, in any fashion, form or manner, either directly or indirectly, unless expressly consented to in writing by an executive officer of the Company, use, divulge, disclose or communicate to any person or entity any confidential information of any kind, nature or description concerning any matters affecting or relating to the business of the Company. The parties to this Agreement hereby stipulate that, as between them, the above information and items are important, material and confidential trade secrets that affect the successful conduct of the Company’s business and its goodwill, and that any breach of any term of this section is a material breach of this Agreement. All equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists or other written and graphic records, and the like, including tangible or intangible computer programs, records and data, affecting or relating to the business of the Company, which the Executive might prepare, use, construct, observe, posses or control, shall be and shall remain the Company’s sole property.

(ii) For purposes of this Agreement, the term “confidential information” shall not include any information that: (A) has been made public by the Company (other than by acts or omissions of Executive in violation of this Agreement or other obligation of confidentiality); (B) is developed by Executive independently of any information the Executive learns in the course of fulfilling her duties hereunder; or (C) Executive is legally compelled to disclose; provided that (1) Executive is advised by written opinion of the Executive’s counsel, who shall be reasonably satisfactory to the Company, that she is legally required to disclose such information and (2) Executive notifies the Company of such proposed disclosure as far in advance of its disclosure as is practicable and uses her best efforts to obtain assurances that confidential treatment will be accorded to such information.

(b)  Non-Interference . Any wrongful interference with the Company’s business, property, confidential information, trade secrets, clients, customers, employees or independent contractors by Executive or any of Executive’s agents during or after the term of Executive’s employment shall be treated and acknowledged by the parties as a material breach of this Agreement. If such interference occurs at a time that Executive is employed by the Company, such interference shall be grounds for the Company to terminate Executive for Cause.

5.2 Remedies . Executive’s duties under this Section 3 shall survive termination of Executive’s employment with the Company. Executive acknowledges that a remedy at law for any breach or threatened breach by Executive of the provisions of this Section 3 would be inadequate, and Executive therefore agrees that the Company shall be entitled to injunctive relief in case of any such breach or threatened breach.

6. Outside Activities .

6.1 Activities . Executive will not during her employment with the Company undertake or engage in any other employment, occupation or business enterprise (other than enterprises in which Executive is a passive investor; provided that such passive investment is consistent with this terms of this Agreement, including this Section 4) without the prior written consent of the Board.. Notwithstanding the foregoing, Executive may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of her duties hereunder and are otherwise consistent with this Section 4.

6.2 Investments and Interests . Executive agrees not to acquire, assume or participate in, directly or indirectly, any material position, investment or interest known by her to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.

6.3 Non-Competition .

(a) During her employment by the Company, except on behalf of the

Company, Executive will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever which were known by her to

compete directly with the Company, throughout the world, in any line of business engaged in (or planned to be engaged in) by the Company.

(b) Notwithstanding the foregoing, nothing in this Agreement shall prevent Executive from owning for passive investment purposes less than 1% of the publicly traded common equity securities of any company engaged in the business of the Company (so long as Executive has no power to manage, operate, advise, consult with or control the competing enterprise and no power, alone or in conjunction with other affiliated parties, to select a director, manager, general partner, or similar governing official of the competing enterprise other than in connection with the normal and customary voting powers afforded Executive in connection with any permissible equity ownership).

7.  Other Agreements .

7.1 Employees . For one year immediately following the termination date of Executive’s employment for any reason, Executive agrees not to solicit, attempt to solicit, induce, or otherwise cause any employee of the Company to terminate his or her employment in order to become an employee, consultant or independent contractor to or for any competitor of the Company.

7.2 Noninterference . For one year immediately following the termination date of Executive’s employment for any reason, Executive agrees not to solicit, on Executive’s own behalf or for any entity that is in competition with the Company, any person or entity that is doing business with the Company or is an active prospect to do business with the Company for the purpose of diverting Company’s business or active business opportunities in competition with Company.

8.  Release . In exchange for the benefits and other consideration under this Agreement to which Executive would not otherwise be entitled, Executive shall enter into and execute a release substantially in the form attached hereto as Exhibit B (the “Release Agreement ”) upon her termination of employment. Unless the Release Agreement is executed by Executive and delivered to the Company within 21 days after the termination of Executive’s employment with the Company, and the same is not revoked, Executive shall not receive any severance benefits provided under this Agreement.

9. General Provisions.

9.1 Notices . Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile transmission) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at her address as listed on the Company payroll.

9.2 Severability . Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein or therein.

9.3 Waiver . If either party should waive any breach of any provisions of this Agreement, she or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

9.4 Complete Agreement . This Agreement, together with the exhibits attached hereto and incorporated herein, constitutes the entire agreement between Executive and the Company and it is the complete, final, and exclusive embodiment of their agreement and supersedes any prior agreement written or otherwise between Executive and the Company with regard to this subject matter. It is entered into without reliance on any promise or representation other than those expressly contained herein or therein, and it cannot be modified or amended except in a writing signed by an officer of the Company.

9.5 Counterparts . This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same agreement or plan. Signatures transmitted electronically or via facsimile shall be deemed to be original signatures.

9.6 Headings . The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof or thereof nor to affect the meaning thereof.

9.7 Successors and Assigns . This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of her duties hereunder and she may not assign any of her rights hereunder without the written consent of the Company.

9.8 Arbitration . To provide a mechanism for rapid and economical dispute resolution, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to this Agreement (including the Release Agreement) and its enforcement, performance, breach, or interpretation, will be resolved, to the fullest extent permitted by law, by final, binding, and confidential arbitration before a single arbitrator held in San Diego, California and conducted by Judicial Arbitration & Mediation

Services/Endispute (“ JAMS ”), under its then-existing Rules and Procedures. The parties shall be entitled to conduct adequate discovery, and they may obtain all remedies available to the parties as if the matter had been tried in court. The arbitrator shall issue a written decision which specifies the findings of fact and conclusions of law on which the arbitrator’s decision is based. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof. Unless otherwise required by law, the arbitrator will award reasonable expenses (including reimbursement of the assigned arbitration costs) to the prevailing party. Nothing in this Section 9.8 or in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in a court of competent jurisdiction to prevent irreparable harm pending the conclusion of any such arbitration.

9.9 Governing Law . All questions concerning the construction, validity and

interpretation of this Agreement will be governed by the law of the State of California as applied to contracts made and to be performed entirely within California, excluding the rules on conflicts of law.

1

IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first above written.

LA JOLLA PHARMACEUTICAL COMPANY

By: /s/ Deirdre Y. Gillespie

EXECUTIVE

By: /s/ Gail A. Sloan

2

EXHIBIT B
RELEASE AGREEMENT

I understand that all of my positions with La Jolla Pharmaceutical Company and its subsidiaries and affiliates (collectively, the “ Company ”) terminated effective

(the “ Separation Date ”). The Company has agreed that if I choose to sign this Agreement, the Company will pay me severance benefits (minus the standard withholdings and deductions) pursuant to the terms of the Executive Agreement entered into as of May 24, 2010 between myself and the Company (the “ Employment Agreement ”). I understand that I am not entitled to any severance payment under the Employment Agreement unless I sign this release agreement. I understand that in addition to this severance, the Company will pay me all of my accrued salary and vacation, to which I am entitled by law regardless of whether I sign this release agreement.

In consideration for the severance payment I am to receive under my Employment Agreement, I agree not to use or disclose any of the Company’s proprietary information without written authorization from an executive officer of the Company, to immediately return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control, and to release the Company and its current and former officers, directors, agents, attorneys, employees, stockholder, and affiliates from any and all claims, liabilities, demands, causes of action, attorneys’ fees, damages, or obligations of every kind and nature, whether they are known or unknown, arising at any time prior to the date I sign this release agreement. This general release includes, but is not limited to: all federal and state statutory and common law claims, claims related to my employment or the termination of my employment or related to breach of contract, tort, wrongful termination, discrimination, wages or benefits, or claims for any form of compensation. This release is not intended to release any claims I have or may have against any of the released parties for (a) indemnification as a director, officer, agent or employee under applicable law, charter document or agreement, (b) severance and other termination benefits specifically provided for in my employment agreement which constitutes a part of the consideration for this release, (c) health or other insurance benefits based on claims already submitted or which are covered claims properly submitted in the future, (d) vested rights under pension, retirement or other benefit plans, or (e) in respect of events, acts or omissions occurring after the date of this release agreement.

In releasing claims unknown to me at present, I am waiving all rights and benefits under Section 1542 of the California Civil Code, and any law or legal principle of similar effect in any jurisdiction: “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by her must have materially affected her settlement with the debtor.”

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the federal Age Discrimination in Employment Act of 1967, as amended (the “ADEA”). I have been advised by this writing, as required by the ADEA that: (a) my waiver and release do not apply to any claims that may arise after my signing of this release; (b) I should consult with an attorney prior to executing this release, (c) I have 21 days within

which to consider this release (although I may choose to voluntarily execute this release earlier); (d) I have seven days following the execution of this release to revoke it; and (e) this release will not be effective until the eighth day after this release agreement has been signed both by me and by the Company (“ Effective Date ”).

This release agreement constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by or on behalf of the Company that is not expressly stated herein. This release agreement may only be modified by a writing signed by both me and a duly authorized officer of the Company.

I accept and agree to the terms and conditions stated above:

By:

Date:

ACKNOWLEDGED:
LA JOLLA PHARMACEUTICAL COMPANY
By:
Name:
Title:
Date:

3

CONFIDENTIAL RETENTION AGREEMENT

This Confidential Retention Agreement (“Agreement”) is made by and between La Jolla Pharmaceutical Company (“LJPC”) and Gail A. Sloan. (“Sloan”) with respect to the following facts:

A. Sloan is currently employed by LJPC as the Vice President of Finance pursuant to an Offer Letter dated March 20, 1996, Supplemental Agreement dated February 23, 2004, Amended and Restated Employment Agreement dated February 23, 2006 and Amendment to Executive Employment Agreement dated December 24, 2008 (collectively referred to as “Employment Agreement”), which provides for severance in exchange for a release of all claims, in the event Sloan’s employment is involuntarily terminated without Cause.

B. Due to the negative result of LJPC’s clinical trial, LJPC is considering a merger, liquidation, financing or other transaction (the “Transaction”).

C. LJPC and Sloan previously entered into a Confidential Retention and Separation Agreement and General Release of All Claims (the “Prior Agreement”) dated December 4, 2009, which by its terms expired on March 31, 2010. The Prior Agreement provided for a Retention Bonus of $66,183.53 payable on execution of that Agreement and a severance payment ($132,367.06) upon the earlier of Sloan’s involuntary termination of employment or March 31, 2010. Such severance payment under the Prior Agreement were structured so as to be exempt from application of Internal Revenue Code Section 409A.

D. LJPC and Sloan confirm that Sloan’s Retention Bonus of $66,183.53 paid in December 2009 was earned on March 31, 2010, and that her severance payment of $132,367.06 was in effect a Retention Bonus and was earned on March 31, 2010 and is now payable.

E. LJPC and Sloan confirm that Sloan was not terminated on March 31, 2010 and Sloan’s employment with LJPC will be extended until the first to occur of (1) the closing of a Transaction, (2) an involuntary termination of employment without cause, or(3) July 31, 2010

F. In order to retain Sloan’s services, the parties wish to supersede the severance provisions of the Employment Agreement and the Prior Agreement and proceed in accordance with the terms and conditions in this Agreement.

G. The parties desire to settle all claims and issues that have, or could have been raised, in relation to Sloan’s employment with LJPC and arising out of or in any way related to the acts, transactions or occurrences between Sloan and LJPC to date, including, but not limited to, Sloan’s employment with LJPC or the termination of that employment, on the terms set forth below.

THEREFORE, in consideration of the promises and agreements hereinafter set forth, it is agreed by and between the undersigned as follows:

1. Severance Payment . LJPC agrees to pay Sloan her severance payment of $132,367.06, less all legally required payroll deductions and withholdings, payable in a lump sum on the first regular pay day following the Effective Date of this Agreement.

2. Retention Bonus . LJPC agrees to pay Sloan a Retention Bonus to retain her services for the additional term. The amount of this Retention Bonus will be determined as follows:

•

$52,119.53 should the company determine to dividend the Company’s remaining cash to stockholders

•

$69,492.70 should the Company secure additional funding or be acquired by another company

•

$138,985.40 should the Company secure a product partnership with related financing

The Retention Bonus, less all legally required payroll deductions and withholdings (“Retention Bonus”), is payable in a lump sum on the first regular pay day following the date on which the Board of Directors confirms that one of the events described above has occurred.

3.  General Release . Sloan unconditionally, irrevocably and absolutely releases and discharges LJPC, and any parent and subsidiary corporations, divisions and affiliated corporations, partnerships or other affiliated entities of LJPC, past and present, as well as LJPC’s employees, officers, directors, agents, successors and assigns (collectively, “Released Parties”), from all claims related in any way to Employment Agreement and all transactions or occurrences between them to date, to the fullest extent permitted by law, including, but not limited to, Sloan’s employment with LJPC, the termination of Sloan’s employment, and all other losses, liabilities, claims, charges, demands and causes of action, known or unknown, suspected or unsuspected, arising directly or indirectly out of or in any way connected with Sloan’s employment with LJPC. This general release is intended to have the broadest possible application and includes, but is not limited to, any tort, contract, common law, constitutional or other statutory claims, including, but not limited to alleged violations of the California Labor Code or the federal Fair Labor Standards Act, Title VII of the Civil Rights Act of 1964 and the California Fair Employment and Housing Act, the Americans with Disabilities Act, the Age Discrimination in Employment Act of 1967, as amended, and all claims for attorneys’ fees, costs and expenses. Sloan expressly waives Sloan’s right to recovery of any type, including damages or reinstatement, in any administrative or court action, whether state or federal, and whether brought by Sloan or on Sloan’s behalf, related in any way to the matters released herein. However, this general release is not intended to bar any claims that, by statute, may not be waived, such as claims for workers’ compensation benefits, unemployment insurance benefits, statutory indemnity, and any challenge to the validity of Sloan’s release of claims under the Age Discrimination in Employment Act of 1967, as amended, as set forth in this Agreement.

3. California Civil Code Section 1542 Waiver . Sloan expressly acknowledges and agrees that all rights under Section 1542 of the California Civil Code are expressly waived. That section provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

4. Representation Concerning Filing of Legal Actions . Sloan represents that, as of the date of this Agreement, she has not filed any lawsuits, charges, complaints, petitions, claims or other accusatory pleadings against LJPC or any of the other Released Parties in any court or with any governmental agency.

5. Nondisparagement . Sloan agrees that she will not make any voluntary statements, written or oral, or cause or encourage others to make any such statements that defame, disparage or in any way criticize the personal and/or business reputations, practices or conduct of LJPC or any of the other Released Parties.

6. Confidentiality and Return of LJPC Property . By signing this Agreement, Sloan represents and warrants that Sloan has, or will, return to LJPC on or before the Separation Date, all LJPC property, data and information belonging to LJPC and agrees not use or disclose to others any confidential or proprietary information of LJPC or the Released Parties.

7. Continuing Obligations . Sloan further agrees to comply with the continuing obligations regarding confidentiality set forth in the surviving provisions of the Invention and Confidential Information Agreement signed by Sloan.

8. No Admissions . By entering into this Agreement, the Released Parties make no admission that they have engaged, or are now engaging, in any unlawful conduct. The parties understand and acknowledge that this Agreement is not an admission of liability and shall not be used or construed as such in any legal or administrative proceeding.

9. Older Workers’ Benefit Protection Act . This Agreement is intended to satisfy the requirements of the Older Workers’ Benefit Protection Act, 29 U.S.C. sec. 626(f). Sloan, by this Agreement, is advised to consult with an attorney before executing this Agreement.

9.1 Acknowledgments/Time to Consider . Sloan acknowledges and agrees that the Retention Bonus is a sum to which she is not otherwise entitled absent the signing of this Agreement; (b) Sloan has read and understands the terms of this Agreement; (c) Sloan has been advised in writing to consult with an attorney before executing this Agreement; (d) Sloan has obtained and considered such legal counsel as she deems necessary; (e) Sloan has been given twenty-one (21) days to consider whether or not to enter into this Agreement (although she may elect not to use the full 21-day period at her option); and (f) by signing this Agreement, Sloan acknowledges that she does so freely, knowingly, and voluntarily.

9.2 Revocation/Effective Date . This Agreement shall not become effective or enforceable until the eighth day after Sloan signs this Agreement. In other words, she may revoke her acceptance of this Agreement within seven (7) days after the date she signs it. Sloan’s revocation must be in writing and received by Deirdre Y. Gillespie, M.D., President and Chief Executive Officer, by 5:00 p.m. Pacific Time on the seventh day in order to be effective. If Sloan does not revoke acceptance within the seven (7) day period, her acceptance of this Agreement shall become binding and enforceable on the eighth day (“Effective Date”). The Severance Payment shall become due and payable in accordance with paragraph 1, provided this Agreement has not been revoked.

9.3 Preserved Rights of Sloan . This Agreement does not waive or release any rights or claims that Sloan may have under the Age Discrimination in Employment Act that arise after the execution of this Agreement. In addition, this Agreement does not prohibit Sloan from challenging the validity of this Agreement’s waiver and release of claims under the Age Discrimination in Employment Act of 1967, as amended.

10. Full Defense. This Agreement may be pled as a full and complete defense to, and may be used as a basis for an injunction against, any action, suit or other proceeding that may be prosecuted, instituted or attempted by Sloan in breach hereof.

11. Severability . In the event any provision of this Agreement shall be found unenforceable, the unenforceable provision shall be deemed deleted and the validity and enforceability of the remaining provisions shall not be affected thereby.

12. Applicable Law . The validity, interpretation and performance o f this Agree ment shall be construed and interpreted according to the laws of the United States of America and the State of California.

13. Entire Agreement; Modification . This Agreement and the surviving provisions of the Invention and Confidential Information Agreement previously executed by Sloan, is intended to be the entire agreement between the parties and supersedes and cancels any and all other and prior agreements, written or oral, between the parties regarding this subject matter. Except as expressly amended hereby, all other terms and provision of the Employment Agreement shall remain in full force and effect. This Agreement may be amended only by a written instrument executed by all parties hereto.

THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATES SHOWN BELOW.

Dated: May 24, 2010
By: /s/ Gail A. Sloan
Gail A. Sloan
La Jolla Pharmaceutical Company

Dated: May 24, 2010
By: /s/ Deirdre Y. Gillespie
Deirdre Y. Gillespie M.D.
President and Chief Executive Officer
La Jolla Pharmaceutical Company